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Summary
In order to deliver drugs to diseased cells nanoparticles featuring controlled drug release are de-
veloped. Controlled release is of particular importance for the delivery of toxic anti-cancer drugs
that should not get in contact with healthy tissue. To evaluate the effectivity and controlled drug-
release ability of nanoparticles in the target cell, live-cell imaging by highly-sensitive fluorescence
microscopy is a powerful method. It allows direct real-time observation of nanoparticle uptake into
the target cell, intracellular trafficking and drug release. With this knowledge, existing nanoparticles
can be evaluated, improved and more effective nanoparticles can be designed. The goal of this work
was to study the internalization efficiency, successful drug loading, pore sealing and controlled drug
release from colloidal mesoporous silica (CMS) nanoparticles. The entire work was performed in
close collaboration with the group of Prof. Thomas Bein (LMU Munich), where the nanoparticles
were synthesized.
To deliver drugs into a cell, the extracellular membrane has to be crossed. Therefore, in the first
part of this work, the internalization efficiency of PEG-shielded CMS nanoparticles into living HeLa
cells was examined by a quenching assay. The internalization time scales varied considerably from
cell to cell. However, about 67% of PEG-shielded CMS nanoparticles were internalized by the cells
within one hour. The time scale is found to be in the range of other nanoparticles (polyplexes,
magnetic lipoplexes [1, 2]) that exhibit non-specific uptake.
Besides internalization efficiency, successful drug loading and pore sealing are important parameters
for drug delivery. To study this, CMS nanoparticles were loaded with the anti-cancer drug colchicine
and sealed by a supported lipid bilayer using a solvent exchange method (additional collaboration
with the group of Prof. Joachim Rädler, LMU). Spinning disk confocal live-cell imaging revealed
that the nanoparticles were taken up into HuH7 cells by endocytosis. As colchicine is known to ex-
hibit toxicity towards microtubules, the microtubule network of the cells was destroyed within 2 h of
incubation with the colchicine-loaded lipid bilayer-coated CMS nanoparticles. Although successful
drug delivery was shown, it is necessary to develop controlled local release strategies.
To achieve controlled drug release, CMS nanoparticles for redox-driven disulfide cleavage were syn-
thesized. The particles contain the ATTO633-labeled amino acid cysteine bound via a disulfide
linker to the inner volume. For reduction of the disulfide bond and release of cysteine, the CMS
nanoparticles need to get into contact with the cytoplasmic reducing milieu of the target cell. We
showed that nanoparticles were taken up by HuH7 cells via endocytosis, but endosomal escape seems
to be a bottleneck for this approach. Incubation of the cells with a photosensitizer (TPPS2a) and
photoactivation led to endosomal escape and successful release of the drug. In addition, we showed
that linkage of ATTO633 at high concentration in the pores of silica nanoparticles results in quench-
ing of the ATTO633 fluorescence. Release of dye from the pores promotes a strong dequenching
effect providing an intense fluorescence signal with excellent signal-to-noise ratio for single-particle
imaging. With this approach, we were able to control the time of photoactivation and thus the time
of endosomal rupture. However, the photosensitizer showed a high toxicity to the cell, due to its
v
presence in the entire cellular membrane.
To reduce cell toxicity induced by the photosensitizer and to achieve spatial control on the endoso-
mal escape, the photosensitizer protoporphyrin IX (PpIX) was covalently surface-linked to the CMS
nanoparticles and used as an on-board photosensitizer (additional collaboration with the groups of
Prof. Joachim Rädler and Prof. Heinrich Leonhardt, both LMU). The nanoparticles were loaded
with model drugs and equipped with a supported lipid bilayer as a removable encapsulation. Upon
photoactivation, successful drug delivery was observed. The mode of action is proposed as a two-
step cascade, where the supported lipid bilayer is disintegrated by singlet oxygen in a first step
and the endosomal membrane ruptures enabling drug release in a second step. With this system,
stimuli-responsive and controlled, localized endosomal escape and drug release is achieved.
Taken together, the data presented in this thesis show that real-time fluorescence imaging of CMS
nanoparticles on a single-cell level is a powerful method to investigate in great detail the processes
associated with drug delivery. Barriers in the internalization and drug delivery are detected and can
be bypassed via new nanoparticle designs. These insights are of great importance for improvements
in the design of existing and the synthesis of new drug delivery systems.
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1 Introduction
66% of the German population estimate the risk of nanotechnology to be lower than its benefits.
This statement is one conclusion of a study on public perceptions about nanotechnology, conducted
by the German Federal Institute for Risk Assessment (BfR) in 2008. According to this study, 77% of
the respondents state to have a good or very good feeling about this technology, but the acceptance
is not equally distributed over all areas of nanotechnology [3]. For example, nanotechnology in the
food sector is viewed critically, whereas nanotechnology in medicine is one of the areas connected
with the highest expectations [3]. However, the shaping of the public opinion on the subject of
nanotechnology is not at its end.
To help that public expectations remain realistic, it is important to maintain a dialog with the
media and the public. One example for this was presented in the TV show “Faszination Wissen”
in Bavarian Television (Bayrisches Fernsehen) broadcasted in March 2011, where scientists, among
others Prof. Christoph Bräuchle from the LMU Munich and Prof. Christian Plank from the TU
Munich, presented their research and opinions on nanomedicine. The key message of the show can
be summarized as follows: nanotechnology is still struggling with reservations, but first success
stories from the clinics, especially with novel drug delivery systems against cancer, are raising great
hopes.
A drug delivery system is, on a symbolic level, a nanoscale “trojan horse”. Its purpose is to transport
drugs to target cells, while remaining unrecognized by the defense system of the body, and to release
the drug at its destination. Thereby, side effects or damage on healthy cells shall be reduced and
cellular treatment shall be limited to the target cells. However, in reality, the design of such a
drug delivery device is non-trivial due to manifold requirements on the system. Amongst others,
the nanoparticle as a carrier system should show low toxicity and be metabolized and eliminated
quickly after cargo delivery.
Immense efforts are undertaken to develop drug delivery systems for the treatment of cancer [4].
This is of great importance as cancer is and will remain one of the most common causes of death.
The WHO prognoses an increase in cancer-caused deaths of up to 9 millions in the year 2015 and
11.4 millions in the year 2030 [5]. In addition, cancer therapies are limited to a combination of
surgery, radiation, and chemotherapy. For this reason, great hope is pinned on the development of
new drug delivery devices which could especially help in chemotherapy.
For drug delivery, various nanoparticle designs have been established, mainly based on polymers and
liposomes. In addition, inorganic nanoparticles, such as silica nanoparticles, have been developed.
This study concentrates on colloidal mesoporous silica (CMS) nanoparticles. They are particularly
interesting due their large surface area and pore volume leading to an efficient encapsulation of high
amounts of guest molecules [6–8]. In addition, CMS nanoparticles can be functionalized at will [9]
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and form stable colloidal suspensions [10].
Due to these advantages, CMS nanoparticles have been investigated intensively by various research
groups. Although there are multiple synthesis and in vitro-functionality studies of CMS nanopar-
ticles, detailed investigations on the mechanism of action in living cells, regarding cellular uptake,
intracellular processing and function, are oftentimes missing. To fill this gap of knowledge, highly-
sensitive fluorescence wide-field and spinning disk confocal microscopy on a single-cell level are
powerful tools. Using these methods, we were able to observe the uptake, intracellular trafficking
and drug delivery processes of single nanoparticles in real-time. These insights enable evaluation
and continuous improvement of the CMS nanoparticles for drug delivery.
As drug delivery is a multi-step process, the nanoparticles have to fulfill certain demands on the
target-cell level. One demand on the drug delivery vehicle is to attach to the target cell and to be
internalized. In this work, we therefore studied the internalization time scale of CMS nanoparticles
equipped with a polyethylene glycol (PEG)-shell into living cervix carcinoma cells (HeLa). The
PEG coating shields the nanoparticle to avoid elimination of the nanoparticles from the body before
reaching the target cell. This increases the nanoparticle’s lifetime in the blood circulation [11].
Another demand of major importance is the high drug-loading into the CMS nanoparticles and pore
sealing to protect the drug from the external milieu. For this reason, we loaded fluorescent dyes and
(model-) drugs by incubation of the CMS in a drug-containing solution (drug adsorption). After
adsorption of the drugs, the pores were sealed by a supported lipid bilayer. Drug delivery of the
loaded substances to liver cancer cells (HuH7) has then been monitored by live-cell imaging.
A third demand involves controlled site-specific and stimuli-responsive release of the drug from the
carrier. To achieve this, we exploited two external stimuli: changes in redox-potential and light irra-
diation. In the first study, the amino acid cystein was bound to the inner volume of the nanoparticle
via a redox-cleavable disulfide linker. Upon internalization into the reducing milieu of the cytoplasm,
this disulfide bridge was supposed to be cleaved setting free the cysteine. To support endosomal
escape photochemical internalization (PCI) was used for delivery of cysteine into the cytoplasm. In
a next step, to achieve a more precise, “surgical” function of photoinduced endosomal release and
to minimize the toxicity of the nanoparticles on cells, we used a covalently surface-bound photo-
sensitizer (PpIX) on CMS and coated the drug-loaded nanoparticles with a supported lipid bilayer.
We studied the drug delivery processes after light irradiation in great detail by fluorescence live-cell
imaging.
This thesis is structured as follows:
The introductory chapter (Chapter 1) is followed by three further chapters covering the theoretical
background and status quo of the research fields that influenced this work.
Chapter 2 describes the principles of nanomedical drug delivery, with an introduction into uptake
and trafficking of nanoparticles in cells and an overview about commonly used drug delivery sys-
tems. Chapter 3 focuses on the drug delivery system used in this work, which is colloidal mesoporous
silica (CMS). The material class will be introduced along with the synthesis strategies developed
by and used in the group of Prof. Thomas Bein. Subsequently, the demands on CMS nanoparticles
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as drug delivery system will be explained along with considerations regarding the biocompatibility.
Chapter 4 describes the principles of fluorescence and the phenomena of bleaching and quenching.
The fluorescence microscopy set-ups are explained as well as the benefits of fluorescence microscopy
in living cells.
Following the chapters on theory, the experimental methods are described in Chapter 5.
In Chapters 6 to 9, the results and discussions of our studies are presented in a partly cumula-
tive manner. Chapter 6 describes the experiments concerning the internalization dynamics of CMS
nanoparticles into living cells. Chapter 7 presents, in its first part, results on drug delivery by lipid
bilayer-coated CMS nanoparticles loaded with colchicine, an anti-cancer drug. The results described
in this chapter are published in Nano Letters [12]. In the second part of the chapter, additional
experiments investigate the influence of the lipid bilayer composition on CMS nanoparticle uptake
into cells. In Chapter 8 disulfide-based drug delivery and the role of photochemical internalization is
presented. The study is published in Nano Letters [13]. To induce photochemical release in a more
locally confined manner, we studied CMS nanoparticles with covalently surface-bound PpIX and its
interaction with living cells. This study is presented in Chapter 9 and submitted for publication
[14]. At the end of each chapter a summary of the main results is provided.
3

2 Principles of nanomedical drug delivery
Many diseases such as cancer are linked to changes in biological processes at the molecular level [15].
These changes can be caused by mutated genes, misfolded proteins and viral or bacterial infections.
To specifically treat these diseases at the molecular level, nanotechnology with materials, especially
particles in the 1-1000 nm range, has contributed significantly [16]. As an offshoot of nanotechnology,
the discipline nanomedicine involves “highly specific medical interventions at the molecular scale for
curing diseases or repairing damaged tissues” [17]. Nanomedicine as a discipline is subdivided into
different fields, one of it being novel drug delivery systems [18, 19]. These systems are currently
subject of immense research efforts, especially for the treatment of cancer.
Conventional cancer treatment involves the application of small molecule cytostatics for chemother-
apy. However, these drugs lack selectivity for cancer tissue leading to considerable toxicity to healthy
tissue and are prone to cause multidrug resistances in cancer cells [20]. To solve these and other
issues, cancer drug delivery has been introduced. Drug delivery involves a pharmaceutical carrier,
called nanoparticle, associated with a drug [21, 22]. Nanoparticles are useful, as they represent in-
tracellular drug depots with sustained release profiles and protect the drug against degradation [23].
In addition, nanoparticles have the ability to be internalized into cells without being recognized by
eﬄux transporters, main mediators of multidrug resistance such as multi-drug resistance proteins
and P-glycoproteins [24].
Commonly used drugs range from nucleic acids (plasmid DNA, siRNA and antisense oligonu-
cleotides) [25, 26]) to small molecule drugs, proteins or imaging agents [27]. Drug delivery can
be achieved even with drugs showing poor water solubility [28]. Some of the novel drug delivery
systems have already been approved by the Food and Drug Administration (FDA), such as Doxil,
liposome-encapsulated doxorubicin with a polyethylene glycol (PEG) coat for treatment of ovarian
cancer and multiple myeloma [20].
Our work focuses on nanometric drug delivery systems for cancer therapy. To evaluate the drug
delivery mechanism on the level of individual cancer cells, the interaction of drug-loaded nanopar-
ticles with cancer cells have to be studied [1, 2, 29, 30]. These processes include uptake of the
nanoparticles into the cells, intracellular trafficking and controlled drug release into the cell.
In the following, the state of knowledge about nanoparticle uptake and intracellular trafficking will
be described. Afterwards, an introduction into commonly used nanoparticle designs will be given.
2.1 Uptake and trafficking of nanoparticles in cells
To administer drug delivery systems into the human body, several modes including oral applica-
tion, inhalation, intravenous and intraperitoneal injection are used [27]. Depending on the mode of
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Tumor
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Figure 2.1: Passive tissue targeting by the enhanced permeability and retention (EPR) effect.
Enhanced permeability of the tumor vasculature and ineffective lymphatic drainage leads to extravasation
and accumulation of nanoparticles in tumor tissue. Figure adapted from [31].
administration, different types of barriers have to be crossed to reach the tumor tissue under min-
imum loss of quantity and activity (accumulation at the target tissue). In subsequent steps,
nanoparticles should selectively internalize into diseased cells without affecting healthy cells [24]
(cellular internalization), get transported to the site of action and release their cargo efficiently
(intracellular transport and endosomal release).
2.1.1 Accumulation at the target tissue
Nanoparticles can accumulate either passively in tumor tissue or by active tumor targeting [32].
This two accumulation modes will be discussed in the following.
Passive accumulation of nanoparticles in tumor tissue is mediated by the enhanced permeability
and retention (EPR) effect [33]. This effect is a feature of many tumors and was first described by
Matsumura et al. [34]. Nanoparticles, running with the blood flow, extravasate into the surrounding
tumor tissue through the endothelial cell layer that exhibits holes. The holes enable macromolecules
or nanoparticles smaller than 400-600 nm [35] to pass. The defective vascular architecture is a result
of rapid tumor growth [31, 36] and consequential need for increased supply with nutrients via the
blood flow. To supply the tumor with nutrients additional tumor vasculature is formed rapidly
and with a lack of a tight endothelial cell layer. In addition, poor lymphatic drainage extends
the residence time of extravasated substances in cancer tissue [37]. A schematic representation of
the EPR effect can be found in Figure 2.1. Despite the positive effects of EPR on nanoparticle
drug delivery, the EPR effect has its limitations. The permeability of vessels is not homogeneous
throughout a tumor and certain tumors show no EPR effect [31]. Therefore, an alternative involves
physical targeting of e.g. magnetic nanoparticles that are accumulated at the target site by magnets
[38]. Once at the target site or tissue, active targeting strategies on a single cell level are beneficial
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to accumulate drugs specifically in tumor cells.
Active targeting strategies for specific tumor-cell accumulation are based on the incorporation of
targeting ligands into particles. The ligands bind to cell type specific receptors expressed on cell
surfaces promoting active cellular uptake [39]. Active targeting has been investigated intensively. A
list of applied ligand-receptor pairs can be found inWagner et al. [40]. Taken together, a combination
of passive and active targeting is useful for drug delivery to the cancer cell environment.
2.1.2 Cellular internalization
After reaching the cancer cell environment, the nanoparticle needs to be delivered to the specific
sub-cellular region where its drug cargo is effective. Some drugs require intracellular delivery to tu-
mor cells or to tumor initiating cells [20]. Therefore, it is of great importance to know about uptake,
intracellular trafficking and fate of nanoparticles on a single-cell level. Depending on the internal-
ization mode of nanoparticles into cells, their intracellular fate will differ considerably. The most
common mode of uptake into mammalian cells is endocytosis. This process is characterized by the
internalization of nanoparticles into membrane-bound vesicles (endosomes), formed by invagination
and subsequent pinch-off [41]. Endosomes deliver cargo to specialized structures for sorting, where
the cargo is directed towards intracellular compartments or recycled to the extracellular milieu [42].
In current nomenclature, two different classifications of uptake pathways have been proposed. One
is based on the proteins involved in the endocytic pathway (e.g. clathrin-mediated endocytosis,
caveolae-mediated endocytosis clathrin-and caveolae independent endocytosis and macropinocyto-
sis). The size of the endosomes differs from 50 nm in caveolae-mediated endocytosis to as large as
5 µm in macropinocytosis [41, 43].
In this work, we will distinguish uptake modes according to the second classification. In this clas-
sification, different internalization stimuli on the cell membrane give rise to fluid-phase, adsorptive
and receptor-mediated endocytosis [44].
Fluid phase endocytosis is, in contrast to adsorptive and receptor-mediated endocytosis, a low-
efficiency and non-specific process. In this process solutes are taken up in their extracellular con-
centration [44]. Fluorescent dextrans are, for example, suitable markers of fluid phase pinocytosis
[45]. However, in case of nanoparticle uptake, fluid phase endocytosis is not as relevant as receptor-
mediated and adsorptive endocytosis.
Adsorptive endocytosis is initiated by unspecific interaction of, in our case, nanoparticles with bind-
ing sites on the cell membrane, such as lectin or heparan sulfate proteoglycanes. The latter are
negatively charged and play an important role in electrostatic interactions [46]. Electrostatic inter-
actions with the plasma membrane in general are mediated by the membrane potential of −30 to
−60 mV [47, 48], leading to better association of positively charged nanoparticles with the plasma
membrane [49]. The nanoparticles are concentrated on the cell surface and internalized together
with the membrane region they are interacting with. For a schematic representation see Figure 2.2a.
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Figure 2.2: Uptake and intracellular trafficking of nanoparticles in cells. (a) Adsorptive endocy-
tosis, (b) receptor-mediated endocytosis and (c) fusion with the plasma membrane are possible modes of
internalization of nanoparticles into cells. In addition, nanoparticles can fuse with the endosomal membrane.
Adapted from a figure provided by the courtesy of Dr. Nadia Ruthardt.
Receptor-mediated endocytosis occurs after binding of specific ligands on the particle surface to recep-
tors on the cell membrane. Receptors overexpressed on cancer cells are, for example, the transferrin
receptor (TFR) [50], the folate receptor [51] or the epidermal growth factor receptor (EGFR) [52].
Ligand binding to the receptor is followed by cell entry into endocytic vesicles [41, 53] (see Figure
2.2b). Upon extracellular receptor-binding of the epidermal growth factor (EGF), signal transduc-
tion to intracellular space is activated triggering a multitude of biochemical pathways including
those leading to internalization [54]. To further increase efficiency and specificity, dual-receptor tar-
geting has been exploited for the delivery of polyplexes (polycation complexed with anionic nucleic
acid). Nie et al. equipped polyplexes with the transferrin receptor targeting peptide B6 and an
arginine-glycine-aspartic acid (RGD)-containing peptide for integrin targeting [55].
Fusion of lipids or peptides with the plasma membrane is an internalization mode that bypasses
endosomal uptake (see Figure 2.2c). Fusion of lipid bilayers is assumed to occur in a two-step
process, where first the electrostatic repulsion of membranes in close proximity need to be overcome
and then non-bilayer transition states are generated [56]. Studies by Felgner et al. suggested
lipoplex (cationic lipid complexed with anionic nucleic acid) mediated gene delivery by fusion of the
lipids with the cell membrane [57, 58]. However, later studies found a more pronounced effect of
endocytosis on cellular uptake [59]. Verma et al. managed to achieve particle fusion on the plasma
membrane by coating gold nanoparticles of 6 nm diameter with a shell of hydrophobic and anionic
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ligands regularly arranged in ribbon-like domains of <6 Å width. These nanoparticles penetrate cell
membranes without evidence of membrane disruption [60]. However, endocytosis is a more frequently
used uptake mode for nanoparticles, whereas viruses seem to undergo fusion more often. Stimuli for
enveloped virus-fusion on the plasma membrane can be low pH, processing of the fusogen precursor,
binding to a receptor or a combination [61]. In addition to fusion on the plasma membrane, fusion
with the endosomal membrane is possible as well [62]. It is important to note, however, that not all
drugs would benefit from fusion-mediated cytosolic delivery as the cytosolic milieu is crowded and
motility of substances delivered to the cytosol is strongly impaired depending on their size, structure
and charge [63].
In case of endocytosed nanoparticles, it is important to understand the mechanisms of intracellular
trafficking and endosomal release. These two topics will be discussed in the following.
2.1.3 Intracellular trafficking
Prior to internalization, nanoparticles attach to the cell membrane. The dynamics of the nanopar-
ticles during membrane association can be characterized by slow, directed transport on the plasma
membrane with velocities of 0.015 µm/s and diffusion coefficients of D = 2-4× 10−4 µm2/s, as as-
sessed for magnetic lipoplexes of 390 nm diameter and epidermal growth factor (EGF)-equipped
polyplexes of 270 nm diameter on living HuH7 cells [2, 30]. After attachment, the nanoparticles
are internalized via endocytosis and confined in early endosomes. The milieu in the endosome in
contact with the nanoparticles undergoes a drop in pH from extracellular tumor milieu of 6.6-7.0
(in healthy tissue pH 7.2-7.4) [64–66] to intracellular pH 5.9-6 [67]. In this phase, the dynamics of
the nanoparticles trapped in endosomes is characterized by anomalous and confined diffusion in the
crowded cellular interior with confinement diameters of 0.1-2 µm for both lipoplexes and polyplexes.
Later on this phase is replaced by active transport of the nanoparticle-filled endosomes along micro-
tubules with velocities of 0.5-0.7 µm/s [2, 30]. After maturation from early to late endosomes the pH
changes to pH 5-6 [67]. Late endosomes were shown to fuse with lysosomes where cargo degradation
takes place [41, 53]. This fusion was shown to take place preferably in the juxtanuclear region of
the cell near the microtubule-organizing center [68]. The lumenal environment in lysosomes shows
pH 5-5.5 [67] and contains acid hydrolases [68].
Although endocytosis is a rather efficient uptake route into cells, internalized molecules have a low
availability at the side of action, for example the cytosol or nucleus, as they remain entrapped in
endo/lysosomes. Therefore endosomal escape is one major prerequisite for successful drug delivery.
2.1.4 Endosomal release
To gain access to the cytosol or the nucleus and to prevent degradation, the internalized nanoparticles
need to overcome endosomes or lysosomes. In the following section, mechanisms for endosomal
escape are described. These mechanisms include pH buffering effects, fusion with the endosomal
membrane and photochemical disruption of the endosomal membrane.
To take advantage of pH-buffering effects for endosomal escape, agents with high buffering capacity
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combined with the flexibility to swell in protonated state are essential [69]. Polyamines with titrat-
able secondary and tertiary amines in the physiological pH range, as found in polyethyleneimine
(PEI), show high H+ buffering capacity during acidification of the endosome. The buffering effect
leads to increased H+ pumping and concomitant Cl- influx into the endosome to maintain charge
neutrality. The increased ionic strength leads to water influx, osmotic swelling and endosomal rup-
ture [70–73]. This model is described as “proton sponge effect” [74]. Recently, Yue et al. proposed
that the “proton sponge effect” plays a role, however, not the dominant role for endosomal escape
[75]. In their model, free cationic PEI chains, present after polyplex assembly, help to release poly-
plexes from endosomes. The free cationic PEI chains get embedded inside the anionic cell membrane
via electrostatic interactions and lead to destabilization of the endosomal membrane. In addition,
cationic PEI chains sticking-out from the loaded endosome prevent the formation of endo/lysosomes.
Another strategy for endosomal escape involves destabilization of the endosomal membrane by fusion
that can be induced by the pH sensitive fusogenic lipid dioleoyl-phosphatidylethanolamine (DOPE).
DOPE forms stable lipid bilayers at physiological pH, but changes to a hexagonal structure at pH
5-6. This inverted hexagonal structure can fuse with the endosomal membrane and destabilizes it
[76, 77]. As another mediator of fusion, the pH sensitive hemagglutinin subunit HA-2 derived from
influenza virus can be used. This peptide undergoes conformational changes at low pH and perturbs
the endosomal membrane [78].
A further endosomal escape strategy is light-induced disruption of the endosomal membrane, a
method called photochemical internalization (PCI) [69]. This method involves incubation of cells
with a photosensitizer. The photosensitizer interacts with the cell membranes and is internalized.
Intracellular localization of a photosensitizer is dependent upon its chemical properties (hydrophobic-
ity, charge or amphiphilic character) and size [79]. A photosensitizer that localizes in the endosomal
membrane is disulfonated meso-tetraphenylporphine (TPPS2a). Upon exposure to light, TPPS2a
induces photochemical reactions that lead to rupture of the vesicular membranes followed by release
of the endosomal content into the cytosol [80]. PCI is a promising strategy for the application in
site-specific drug delivery [81] and has been applied for the delivery of genes [30, 82] or other drugs
[83]. However, the application of PCI is limited by the tissue’s strong light absorption. Reduced
tissue absorption is only observed in the range of 800 - 1200 nm light [84]
For the design of a nanoparticle for successful drug delivery, knowledge about uptake, intracellular
trafficking and endosomal escape is essential. In the following, the most common nanoparticle types
for drug delivery will be introduced briefly.
2.2 Nanoparticle designs for drug delivery
To design a successful nanoscale drug delivery system, sophisticated materials are available. These
materials include polymers, dendrimers and lipids that can be assembled into nanocarriers to enhance
the payload and solubility of drugs. In addition, inorganic materials such as ceramics or metals and
metal oxides exhibiting unique optical and magnetic properties are promising materials for drug
delivery. This section introduces different types of nanoparticulate delivery systems employed for
10
2.2 Nanoparticle designs for drug delivery
drugs in the field of nanomedicine with a short overview of their advantages and disadvantages.
2.2.1 Polymeric nanoparticles
Polymeric nanoparticles have been used for gene delivery [85, 86] and delivery of other drugs [16,
87]. They can be prepared from a wide range of materials such as PEI, chitosan, gelatin and
FDA-approved polylactic acid (PLA) and poly(lactic-co-glycolic acid) (PLGA) in various designs.
The cargo is electrostatically or physically entrapped in, or attached to the polymer matrix [88].
One example of a successfully used polymer in drug delivery is polyethylene glycol (PEG). PEG
is used as a coating of nanoparticles and reduces plasma protein adsorption and phagocytosis of
nanoparticles by cells of the reticulo endothelial system (RES) [23]. Most polymer materials show a
good biodegradability and biocompatibility as well as good pharmacokinetic control [23]. Possible
disadvantages of polymeric nanoparticles are that large-scale production and manufacturing remains
an issue [23], that there are still cytotoxicity problems with some polymers [89], e.g. PEI, and that
their drug carrying capacity is comparably low [87].
2.2.2 Lipid-based nanoparticles
Besides polymeric nanoparticles, lipid-based nanoparticles play an important role for drug delivery.
This widely used system is able to load polar molecules to the lipid bilayer’s aqueous core or
absorb nonpolar drugs within the hydrophobic bilayer [90]. The term lipid-based nanoparticles
comprises a variety of different designs including, among others lipoplexes (cationic lipid-nucleic
acid complex) [77, 91, 92] and liposomes [90]. Liposomes are spherical bilayered vesicles with a
phospholipid membrane surrounding a central aqueous space [24, 93]. Liposomes combine ease of
surface functionalization with a good biocompatibility profile. They can be loaded with hydrophilic
and hydrophobic pharmaceuticals, have a high drug carrying capacity [94] as well as adjustable
size, charge and surface properties [23, 87, 93]. However, some drawbacks exist. Liposomes are
eliminated from the blood rapidly and captured by cells of the RES [93]. In addition, they show
low stability in biological media [23].
2.2.3 Viral nanoparticles
Viral nanoparticles are virus-based nanoparticle formulations that can be infectious or noninfec-
tious [95]. Examples for viral nanoparticles include the cowpea mosaic virus, cowpea chlorotic
mottle virus, bacteriophages [96] and recombinant adenovirus [97]. The capsid surface can be mo-
dified using chemical or genetic means to display targeting molecules and peptides in a biologically
functional form [24, 98]. The high delivery efficiency, regular geometries, well-characterized surface
properties, nanoscale dimensions and their structure known to near atomic resolution are advanta-
geous. However, for a safe application of viral nanoparticles as nanocarriers in vivo, immunogenicity
is an issue and it is essential to gain a better understanding of the fate and potential long-term side
effects [95].
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2.2.4 Inorganic nanoparticles
Inorganic nanomaterials as drug delivery systems consist of nanoparticles based on semiconductors,
so-called quantum dots, metals (such as gold and silver), and metal oxides (such as iron oxide and
silicon dioxide) [99]. These materials provide a robust framework for further modifications [7]. One
promising example is gold nanostructures that are used to generate significant heat within tumors
(hyperthermia) and therefore selectively increase the delivery of macromolecules with therapeutic
anti-cancer drugs [100]. General advantage of inorganic nanoparticles is the stability over high
temperature and pH range, but the lack of biodegradation and slow dissolution raises safety questions
[23]. Silica nanoparticles also belong to the class of inorganic nanoparticles with extremely promising
properties. As this material is of major importance for this work, the following chapter focuses on
it.
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nanoparticles
Colloidal mesoporous silica (CMS) nanoparticles are highly promising candidates for the delivery of
diagnostics or therapeutics to diseased cells and have been studied as drug delivery system through-
out this work. Therefore, the following section will be focused on this material class. First, a gen-
eral introduction into mesoporous silica materials is given, followed by an explanation of the CMS
nanoparticle synthesis. As CMS nanoparticles are studied extensively in various research groups,
an overview of the studies on CMS nanoparticles for drug delivery and on their biocompatibility is
provided.
3.1 Mesoporous silica materials
Porous solids with ordered structure have been established from a variety of different materials, but
silica is the most common. Microporous structures are defined to show pore diameters of <2 nm,
whereas mesoporous materials contain pore diameters of 2-50 nm [101]. In 1992, the innovative
synthesis method of Kresge et al. using aluminosilicates in the presence of a surfactant as a structure-
directing agent, enabled to achieve porous material with uniform pore diameters in the mesoscale
and narrow pore-size distributions [102]. This breakthrough revolutionized the field of mesoporous
materials. The reason for mesoporous silica to be such an attractive material can be attributed
to their uniform pore diameter, large surface area, high chemical and thermal stability, and to
the ability to be functionalized at will [103, 104]. Their properties render mesoporous materials
useful for a variety of applications, such as catalysis [105], chemical separations [106, 107] and
biomedical applications such as implants for bone tissue engineering [108] or drug delivery [109, 110].
Mesoporous materials appear in multiple morphologies, for example thin films [111], powders [112]
as well as micro- and nanoparticles in various shapes [113].
In this work, we focus on mesoporous silica nanoparticles for drug delivery. The nanoparticles were
developed and synthesized by Dr. Valentina Cauda, Dr. Axel Schlossbauer, Christian Argyo and
Alexandra Schmidt from the group of Prof. Thomas Bein (LMU Munich).
3.2 Synthesis of CMS nanoparticles
Colloidal mesoporous silica (CMS) nanoparticles can be described as solid, amorphous silica nano-
materials in suspension with hundreds of empty, mesoporous channels arranged in a porous structure
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Figure 3.1: Cooperative self-assembly of silica precursors around surfactant micelles. Figure
adapted from [106].
[114]. Due to their colloidal stability in certain media [115], biocompatibility [116, 117], degradabil-
ity in living tissue [118], high loading capacity of guest molecules [12, 119, 120], improved pharma-
cokinetics and controlled release kinetics, CMS nanoparticles are of high interest for nanomedical
applications.
In the following, the synthesis of CMS nanoparticles used throughout this study will be explained.
The synthesis is based on cooperative self-assembly of silica precursors around a surfactant template
under basic conditions (see Figure 3.1). The organic surfactant acts as a template and structure-
directing agent introducing the well-defined and uniform mesopore morphology which is one of
the major concerns in CMS synthesis. To limit the particle size the polyalcohol triethanolamine
(TEA) was used as a complexing agent for silicate species and additionally as an encapsulator for
mesoporous particles [10]. In addition, the use of organo-functionalized silane together with the silica
source allows the introduction of chemical functional moieties throughout the porous silica surface.
To achieve multiple functionalities within one particle, the group of Prof. Thomas Bein developed
the delayed co-condensation approach [9]. In this work, two different particle-types, which were
further modified, have been synthesized for this work: outer-shell functionalized CMS and core-shell
functionalized CMS. Both synthesis strategies will be explained briefly in the following.
3.2.1 Outer-shell functionalized CMS
To synthesize outer-shell functionalized CMS [9], the silica source (e.g. tetraethyl orthosilicate,
TEOS) is mixed with triethanolamine (TEA). The reaction mixture is heated for 30 min at 90℃
without stirring. In parallel, the precursor cetyltrimethylammonium chloride (CTAC) solution in
water is prepared and heated to 60℃. The CTAC solution is added to the TEOS/TEA mixture
and stirred at 500 rpm for 20 min (see Figure 3.2a, first step). During this step silicate polyanions
assemble at the positive charges of the cationic surfactant headgroups, which are forming micelles.
The surfactant packing and therefore the pore topology is dependent on the volume of the surfactant,
the headgroup area at the micelle surface and the length of the surfactant tail [121]. In case of the
CMS nanoparticles, the resulting pores in the central areas of the particles are worm-like and radially
diverging towards the boundary of the particles [10]. The mesostructure is formed by continuous
crosslinking and polymerization of the silica species. If an amino-functionality at the CMS shell is
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Figure adapted from [9].
desired, a functionalized trialkoxysilane, in our case (3-aminopropyl)-triethoxysilane (APTES), was
added to the reaction mixture in combination with TEOS at a molar ratio of (1:1) 30 min after the
beginning of the reaction. The resulting mixture was left to stir overnight at room temperature (see
Figure 3.2a, second step). The sample was centrifuged, redispersed in ethanol, and extracted. For
more details, please see Cauda et al. [9].
3.2.2 Core-shell functionalized CMS
As a second particle-type, used in this study, core-shell functionalized CMS were synthesized [9].
To obtain a functionalized core, TEOS was incubated together with TEA and the functionalized
trialkoxysilane (RTES, in our case (3-aminopropyl)-triethoxysilane (APTES) or (3-mercaptopropyl)-
triethoxysilane (MPTES)) at 90℃ for 20 min. The 60℃ -heated CTAC solution was added and the
resulting mixture was stirred at 500 rpm for 20 min. After this synthesis step, an unfunctionalized
silica layer was realized by multiple addition of small portions of TEOS to the reaction mixture
and continued stirring for 40 min (see Figure 3.2b, first step). To functionalize the outer shell
of the CMS a mixture of TEOS and another functionalized trialkoxysilane (1:1) was added and
the reaction mixture was stirred at room temperature overnight (see Figure 3.2b, second step),
centrifuged, redispersed in ethanol, and extracted. For more details, please see Cauda et al. [9].
3.2.3 Template extraction
To make the pores accessible after successful synthesis, it is necessary to remove the organic template.
In our case, the template was extracted by heating the colloidal suspension in ethanolic ammonium
nitrate solution to 90℃ for 45 min under reflux [9]. Ammonium is a very efficient extraction reagent,
as it has high similarity with the template headgroups [122]. Subsequently, a washing step in
ethanol followed by centrifugation was performed. In a second step the suspension was kept in
ethanol/hydrochloric acid solution for additional 45 min and was afterwards washed in ethanol.
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3.3 CMS nanoparticles as drug delivery vehicles
The described synthesis leads to well-defined CMS nanoparticles of 50-80 nm with a wormlike meso-
porous structure, pore diameters of about 3.7 nm and site-specific functionalities. These functionali-
ties can be further modified to meet the requirements of drug delivery devices. The first requirement
is that the nanoparticles should have high drug loading capacity and the loaded substances should
be protected from external milieu to avoid cargo destruction (drug loading). Second, the loaded
substances should show zero premature release and remain inside the drug carrier during transport
to the target side (pore sealing). Third, the drug delivery vehicle should be taken up by the target
cell efficiently (cancer cell targeting). Fourth, drug delivery should occur in a site-specific and
stimuli-responsive manner (stimuli-responsive release). Fifth, the drug delivery vehicle has to be
biodegradable and biocompatible and has to be excreted/degraded by the patient after it achieved
successful drug delivery (degradation and nanotoxicity considerations). The aforementioned
requirements will be further addressed in the following.
3.3.1 Drug loading
To load high quantities of drugs into CMS nanoparticles, two different strategies can be applied. On
the one hand, the drug of interest can be covalently linked to the nanoparticle (e.g. by click chemistry
[123] or disulfide linkage [13, 124]), on the other hand drugs can be simply loaded by incubation
of CMS in a drug solution (adsorption) [125]. In the latter case, the amount of drug loaded in the
porous matrix depends on multiple factors such as the solvent, the pH and the drug concentration
used during CMS incubation with the drug, the pore size of CMS and functionalization of the
pore walls [126]. For a controlled adsorption of the drug, the choice and modulation of adequate
electrochemical surface properties is important [127].
Generally, both hydrophilic and hydrophobic drugs can be loaded into mesoporous silica nanoparti-
cles (MSN). Various cargos have been loaded and published, including genetic information encoded
in DNA and (si)RNA [128], quantum dots [128], toxins [128] and pharmaceuticals (vancomycin [129],
ibuprofen [125], telmisartan [130]). For cancer treatment, cytostatics such as colchicine [12], camp-
tothecin [131], doxorubicine [128, 132, 133], cisplatin [128] and 5-fluoruracil [128] are relevant drugs
for CMS loading. In addition, neurotransmitters (adenosine triphosphate (ATP) [129]) or second
messenger (cyclic adenosine monophosphate (cAMP) [134]) and model-drugs such as membrane-
impermeable proteins (cytochrome c [119]), dyes (propidium iodide (PI) [131, 135], DiI/DiO [136],
rhodamine B [137], safranine O [138], fluorescein [139–141]) as well as dye-labeled dextran e.g.
40 kDa FITC-dextran [142] have been tested as cargos and loaded into the pores.
3.3.2 Pore sealing
After drug loading, it is essential to avoid pre-mature drug leakage from the carrier, as this might
induce systemic toxic effects. Therefore, a number of strategies for pore sealing have been developed.
One important strategy is capping of the entire CMS nanoparticle by a supported lipid bilayer (SLB)
as reported by Brinker et al. [128, 143, 144] and Bein et al. [12]. In the latter publication, the SLB
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Figure 3.3: Pore sealing
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is built via solvent exchange by increasing the water content in the ethanolic suspension containing
lipids and nanoparticles. The nanoparticles are enclosed and the membrane-impermeable cargo
inside the pores is prevented from release (see Figure 3.3). This promising strategy has been applied
in our own research and will be presented in Chaper 7 of this thesis.
Another strategy involves the use of peptides or proteins on the opening of the pores. Schlossbauer et
al. reported on a biotin-avidin cap system [140]. Zhao et al. blocked the pore openings with insulin
proteins [134]. Climent et al. used antibodies [145] and Luo et al. collagen [146] as a nanoscopic
cap. Coll et al. took advantage of a peptide shell to reduce premature release [147]. Pore sealing
was also achieved by inorganic nanoparticles as “gate-keepers”, including CdS nanocrystals [129]
or gold nanoparticles [138, 139, 141]. Also polymers [136, 148], dendrimers [132], sugar [149] and
DNA double strands [150] have been used. A variety of strategies developed by Zink et al. include
complex, supramolecular assemblies for pore sealing [131, 135, 137, 151–159].
3.3.3 Cancer cell targeting
Selective cancer-cell targeting is a important task, as anti-cancer drugs have severe side-effects
caused by unspecific action on healthy cells. Therefore, receptors overexpressed on cancer cells can
be targeted by nanoparticles, leading to efficient internalization of the drug carriers by receptor-
mediated endocytosis (for details on the cellular uptake pathways, please see Chapter 2.1). Receptor-
targeted MSN have been synthesized by many groups.
Most studies were performed using the specific interaction of folic acid with the α-folate receptor
upregulated in various types of human cancers. Zink and coworkers showed the synthesis of MSN
with an iron oxide core and surface grafted folate-silanes. They observed increased particle uptake
into a pancreatic cancer cell line (PANC-1) compared to non-cancerous cells [7]. In another study,
folic acid has been bound to a polyethyleneimine (PEI) shell. Cell culture studies show that the
total number of particles internalized by folate-receptor overexpressing cells was about an order of
magnitude higher compared to control cells with a low number of folate-receptors [160]. Similar
studies on folic acid-functionalized MSN have been performed by other groups [161, 162].
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Another receptor-ligand is lactobionic acid (LA) which binds specifically to the asialoglycoprotein
receptor (ASGP-R) on the surfaces of hepatoma cells. Endocytosis efficiencies into HepaG2 (human
liver hepatocellular carcinoma cell line) cells were shown to be three times higher for LA-MSN
compared to untargeted MSN after 2 hours [146].
In a very recent study by Zink et al., the cyclic RGD peptide and the protein transferrin have been
covalently bonded to MSN and hydrophobic drug delivery of the anti-cancer drug camptothecin has
been achieved [163]. Another recent study by Brinker et al. applied a SLB on CMS containing
targeting peptides (SP94) and fusogenic peptides (H5WYG) and showed successful receptor target-
ing and cargo delivery [128]. Monoclonal antibody-functionalized (anti-HER2/neu mAb) MSN have
successfully targeted breast cancer cells [164].
In addition, cancer cell-specific DNA aptamers, single strand nucleic acids that bind to their target
molecules with high affinity and specificity, have been presented as targeting ligand on MSN. The
aptamer binds to its target protein, the human protein tyrosine kinase-7, present on some tumor cells
surfaces (e.g. on HeLa cells). Upon binding, aptamer-MSNs show highly efficient aptamer-mediated
endocytosis [165].
Some studies show uptake of MSN upon binding to the mannose receptor. For example there is
mannose on a photosensitizer (anionic porphyrin) that is covalently linked to MSN [166], mannosy-
lated PEI-coupled MSN [167] and MSN methotrexate, which binds to the mannose receptor and is
in addition a cytostatic [168].
3.3.4 Stimuli-responsive release
After CMS drug loading, pores are sealed and the nanoparticles internalize specifically to cancer
cells. As a final step, release of the loaded drug is an important challenge. This is due to the
toxicity and severe side-effects induced by these drugs on healthy tissue. Therefore, these drugs
should be delivered with control over the space and time of the release process, preferably upon
a defined stimulus. Several groups have reported upon stimuli for controlled release. The triggers
of stimuli-responsive drug release include competitive displacement, magnetic field, enzymatic di-
gestion, changes in temperature, pH, redox-potential and light irradiation. The triggers will be
addressed in more detail in the following.
Competitive displacement
Competitive displacement is a trigger used in case of aptamer-modified gold nanoparticles that cap
the pores of MSN by binding of aptamer to adenosine on the pore exterior of MSN. The addition
of ATP leads to competitive displacement of adenosine and disrupts the adenosine-aptamer interac-
tion [139] (see Figure 3.4a). In another approach, phenylboronic acid on the surface of MSN binds
reversibly to gluconic acid-modified insulin serving as caps on the mesopores. The introduction of
saccharides leads to uncapping of the system and release of the guest molecules [134]. In a third
approach, antibodies against sulfathiazole bind to hapten on surface of mesoporous silica support.
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Figure 3.4: Stimuli for controlled drug release from MSN. (a) Competitive displacement (adapted
from [139]).(b) Magnetic field (adapted from [169]). (c) enzymatic digestion (adapted from [147]). (d)
temperature (adapted from [170]). (e) Change in pH value (adapted from [133]). (f) change in redox milieu
(adapted from [129]). (g) light irradiation (adapted from [141]).
However, upon addition of sulfathiazole, the antibody is removed from its unspecific target [145].
Magnetic fields
Magnetic fields are used as release trigger as shown by Thomas et al. [169]. Zinc-doped iron oxide
nanocrystals within a MSN were synthesized and the pores were sealed by a molecular machine con-
sisting of cucurbit[6]uril, which electrostatically binds a molecular thread on the silica nanoparticle
surface and prevents the cargo from leaching out of the MSN pores [135]. An alternating current
magnetic field leads to the generation of local internal heat by the nanocrystals and causes the
molecular machines to disassemble enabling drug release [169] (see Figure 3.4b).
Enzymatic digestion
Enzymatic digestion of the gatekeeping agent has been reported as another interesting approach
for stimuli-responsive release. Stoddart et al. presented “snap-top” nanovalves on the surface of
MSN, consisting of threads with α-cyclodextrin (α-CD) rings capped with ester-linked adamantyl
stoppers. This construct is intact and prevents dyes from leaching out of the pores. Porcine liver
esterase catalyses the hydrolysis of the adamantyl stoppers, leading to loss of the α-CD rings and
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release of the cargo [156]. In another study a lactose derivative was used as a “gatekeeper” on the
surface of mesoporous silica support. The enzyme β-D-galactosidase catalyzed the hydrolysis of
the disaccharide lactose into the monosaccharides galactose and glucose followed by release of the
loaded dye [149]. In a follow-up study, complex peptide sequences were anchored by click chemistry
on the MSN. No release of the loaded dye was observed. Only after addition of proteolytic enzymes
that cleaved the peptide sequences, dye release from MSN was observed [147] (see Figure 3.4c).
Schlossbauer et al. presented an enzyme-responsive drug delivery system consisting of a biotiny-
lated outer-particle surface. Upon addition of avidin, the well-studied biotin-avidin complex forms
on the particle surface. As an enzymatic trigger trypsin enables the proteolytic digestion of avidin
and re-opening of the pores. In addition, temperature can be used as a stimulus for denaturation of
the avidin protein and pore opening [140]. One strategy with the ability to use both enzymes and
temperature as external stimuli for pore opening has been adapted by Chen et al.. In their study,
DNAse I is used to cleave DNA self-complementary double-strands clicked to pore openings on the
surface of MSNs. In addition temperature induced denaturation of the DNA double strands can be
applied [150].
Temperature
Temperature-induced DNA valve opening has been introduced before by Schlossbauer et al. [170].
For this, biotin-labeled DNA double strands were attached to the pore mouths of the core-shell
CMS nanoparticles. The protein avidin closes the pores. The opening of the valve is achieved by
temperature-induced separation of the DNA strands and removal of avidin from the pore openings
(see Figure 3.4d).
pH
A change in pH is another option to induce controlled release from MSN. Porous silica particles
with a naphtalene-containing dialkylammonium-tether are capped by noncovalent interactions with a
crown-ether. Upon base addition, the crown-ether detaches from the tether and the cargo is released
[152]. Another approach published by Zink et al. involves chemically fine-tuned trisammoniuim
stalks tethered to the MSN orifices and encircled by cucurbit[6]uril (CB[6]) pseudorotaxanes. At
neutral pH, the position of CB[6] on the stalk is such that the pores are sealed, however upon
increase or decrease of the pH an opening of the pores is induced due to a change in position of
CB[6] [135].
In a recent study, Muhammad et al. used ZnO quantum dot lids on MSNs which are efficiently
dissolved in the acidic intracellular compartments of cancer cells. Using this system, the authors
showed doxorubicine delivery to HeLa cells [171].
Another approach involves the use of a polymethacrylic acid-co-vinyl triethoxysilane (PMV) shell
on mesoporous silica spheres that is in a loose and open state at pH 7.5 and in a compact and
closed state at pH 4-5 [148]. Cauda et al. demonstrated, that selective functionalization of the pore
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openings with both amino and sulfonate groups leads to ionic interactions of the two functional
groups at acidic pH values and pore closure. It was shown that this gating system is applicable
to base-induced release of the drug ibuprofen [125]. Apart from systems with a cap on the pore
opening, pH-sensitive linkers, like hydrazone bonds were used to conjugate doxorubicin into the
pores of MSN. The hydrazone bonds can be successfully cleaved at endosomal pH [133] (see Figure
3.4e).
Redox potential
Changes in the redox potential can also act as stimuli for controlled release. Most strategies uti-
lize the reducing milieu of the cellular cytoplasm to cleave disulfide bridges. In one study, MSN
end-capped with collagen was synthesized. Collagen is one component of the extracellular matrix
of cells. The collagen immobilization on MSN was achieved by disulfide bonds which can be cleaved
under reducing conditions [146]. Others used a disulfide-linked polymeric network as a “gatekeeper”
on mesoporous silica particles. Poly(N-acryloxysuccinimide) was used for this purpose and the poly-
meric network was shown to be opened by reductive milieu [172]. Ambrogio et al. contributed to
the field by introducing their redox-responsive “snap-top” nanovalves consisting -in this case- of
threads with α-CD or CB[6] rings capped with disulfide-linked adamantyl stoppers. Upon addition
of the strong reducing agent dithiothreitol (DTT) or 2-mercaptoethanol (ME), cargo release from
the nanoparticles was observed [159]. Lin et al. succeeded to attach disulfide-bridged cadmium
sulfide (CdS) nanoparticles to the voids of MSN to physically block premature cargo release, which
was later induced by DTT [129] (see Figure 3.4f). Later an alternative strategy was proposed. For
this, a membrane-impermeable cystein was linked into the pores of MSN by disulfide bridges. The
study showed successful delivery of the cystein inside the cells. With this approach, the Lin group
circumvented the problem of pore-capping [124]. A detailed study on disulfide-based drug delivery
from CMS will be presented later in this thesis (see Chapter 8).
Light irradiation
Light irradiation can induce photochemically-controlled drug release. Various studies by the Zink
group show that azobenzene derivatives can act as both gatekeepers and impellers in and on meso-
porous silica nanoparticles. In detail, excitation with 457 nm light induces constant cis-trans isomer-
ization reactions of N=N bonds in azobenzene and concomitant expulsion of the loaded cargo from
MSN [131, 154]. In addition, the Zink group showed, that β-CD rings on azobenzene-containing
stalks bind to trans-azobenzene units and seal the pores of MSN. After irradiation and isomerization
from trans to cis- azobenzene the gates are opened and the cargo is released [157]. The establish-
ment of a system applicable to living cells was the focus on the study by Vivero-Escoto et al. The
authors capped MSN with gold nanoparticles via a photolabile linker which is positively charged in
the MSN-bound state, but negatively charged in the MSN-unbound state. Light irradiation leads to
a charge repulsion between the gold nanoparticles and MSN and uncapping of MSN [141] (see Figure
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3.4g). In our research, we took advantage of photosensitizers used for photochemical internalization
(PCI). These photosensitizers, once excited, can induce endosomal escape (presented in Chapter 8)
and even rupture lipid bilayers surrounding CMS (see Chapter 9) inside living cells .
In summary, many strategies for controlled release have been presented. However, only some of
the developed systems respond to physiologically relevant, easy-to-apply stimuli. Oftentimes the
systems are not applicable in aqueous solutions, are not biocompatible or include toxic capping
agents.
3.4 Biocompatibility of CMS nanoparticles
Not only the potential toxicity of capping agents are important to consider, the toxicity and bio-
compatibility of MSN material needs to be studied as well. Numerous groups published data on
biocompatibility and MSN-induced cytotoxicity in cell culture [161, 173] and in vivo [174–176].
A long-term in vivo study of silica disk implants in living mice (1.5 g/kg body weight) showed
no related changes in liver, kidney, uterus or lymph nodes. The implant was biocompatible with
the surrounding tissue [116]. To study the toxicity of mesoporous silica nanoparticles and learn
more about their biodistribution, it is, however, of great importance to consider the interplay of
all key-parameters including size, surface properties and concentration, porosity of MSN as well as
degradation byproducts and their effect on living organisms, tissues and cells.
3.4.1 Size, surface properties and concentration
The size of nanoparticles has an influence on biodistribution and might therefore also have an
influence on toxicity. Generally, the size of nanoparticles for nanomedical applications should be
designed to avoid immediate elimination by the immune system, which occurs more strongly in
the larger size regime of 80-150 nm than at the lower size regime of 20-50 nm [177]. On the other
hand, nanoparticles should be larger than 8 nm to avoid immediate renal clearance [178]. In the
field of MSN, controversial findings have been reported about the effect of size on the cytotoxicity
in vitro. Vallhov et al. reported, that -in case of MSN with diameters of 270 nm and 2.5 µm-
the smaller particles showed lower activation of immune system and therefore lower cytotoxicity
to human monocyte-derived dendritic cells (MDDCs) [179]. Another study by He et al., however,
showed the opposite effect. In case of the examined MSN with sizes of 190 nm, 420 nm and 1.22µm,
the authors found that the smaller particles show higher cytotoxicity on human breast cancer cells
(MDA-MB-468) and African green monkey kidney cells (COS-7) [180]. Unfortunately none of the
studies examined MSN in the range of 50-100 nm. However, it can be stated that MSNs in the
size range of 100-170 nm show little cytotoxicity in various cell lines at concentrations lower than
100 µg/mL cell medium [181].
In addition to in vitro studies, in vivo studies have been performed. In an in vivo study, MSN with
diameters of 80, 120, 200 and 360 nm have been injected into living mice at a dose of 20 mg/kg.
The mice have been monitored for one month and survived well without pathological abnormalities
[176]. In the same study, MSN were additionally shielded by a PEG coat. PEGylation increases
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Figure 3.5: Hemolysis induced by non-
porous and mesoporous silica nanopar-
ticles. (a) Non-porous silica nanoparticles in
contact with a red blood cell surface induces
hemolysis. (b) Mesoporous silica nanoparti-
cles induce hemolysis to lesser extent due to
the reduced amount of silanol groups on the
particle surface. Figure adapted from [186].
blood-circulation lifetime by avoiding phagocytosis. The PEG-shielded MSN showed the desired
effects in the study be He et al. [176], but also in other studies [182, 183]. PEG linker with a
molecular weight (MW) of 10 k showed the optimal chain density to reduce human serum protein
(HSA) adsorbance and phagocytosis by human macrophages. In addition, PEGylation reduces
hemolysis, the rupture of human red blood cells (HRBCs) and release of their contents into the
surrounding fluid [182]. It was suggested, that hemolysis occurs due to the interaction of silanol
groups of the nanoparticles with tetra-alkyl ammonium groups on the HRBC membrane. It is
noteworthy that MSNs show a reduced hemolytic activity in comparison to silica nanoparticles
without pores due to the voids on the surface of MSNs [184] (see Figure 3.5). Because of the
hemolysis properties of surface silanol groups, it is advantageous to functionalize the silica surface
for better biocompatibility. Positively charged quaternary ammonium groups, for example, were
shown to be a quite biocompatible functionalization [185]. In addition, carboxy- and sulfonato-
functionalized MSN were shown be less active in hemolysis than the unfunctionalized MSNs [186].
Along with particle size and surface properties, the applied nanoparticle concentration is a crucial
parameter, when assessing toxicity. In vitro studies showed, that up to 100 µg/mL of MSN are well
tolerated by cells as examined even after 7 cell cycles [161] or for up to 6 days [187]. In vivo studies
showed no toxic effects on short-term for up to 200 mg/kg in mouse [175, 188], but administration of
1.2 g/kg MSNs is lethal to mice [189]. In the same study, different application routes were compared.
Although subcutaneous administration was fairly well tolerated by rats (75 mg/kg), peritoneal and
intravenous administration of 1.2 g/kg was lethal to mice within 24 hours [189].
3.4.2 Degradation
Biodegradability is a key issue regarding biocompatibility of MSN. An optimal nanoparticle drug
carrier should be degraded and excreted by the body without accumulation. One study reported
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on the structural stability and degradation behavior of mesoporous silica (MS) (particles in nano
to micro range) in simulated body fluid (SBF). The authors describe a three-stage degradation
behavior, including a very fast degradation step within 2 hours in which silica species are released
from MS to a high degree. In the second step the amount of released silica species decreases
due to the deposition of a calcium/magnesium silicate layer on the MS. The third stage shows
very slow degradation heavily depressed by the calcium/magnesium silicate deposition layer with
thorough degradation after 15-days [190]. A study on the degradation of unfunctionalized, phenyl-,
chloropropyl- and aminopropyl-functionalized and poly(ethylene glycol)-coated CMS nanoparticles
in SBF has been presented by Cauda et al. [191]. The authors show a fast degradation in all cases
by broadening of pore-size distribution and loss of mesoporosity due to pore-size increase. CMS
nanoparticles with a PEG-layer, however, showed a considerably decelerated degradation of the
mesopore system in the particles and precipitation of inorganic compounds from SBF solution.
Although the degradation of silica has been studied and elucidated, it is important to learn about
the influence of the degradation products on cells. In one study, it was shown that after 6 days
of degradation an increase in hemolytic activity of MSN was detectable due to the altered surface
structure in comparison to freshly synthesized MSN [184]. However, after 2 hours biodegradation in
PBS, MSN side-products like silicic acids were exposed to human breast cancer cells (MDA-MB-468)
and African green monkey kidney cells (COS-7). The outcome of the study was that no toxic effects
have been detected on the cells [180]. Due to the amount of different parameters influencing toxicity
of MSN on living matter, there has not yet been a study able to take all these parameters into
consideration simultaneously. Therefore, more systematic research need to be performed in vitro
and in vivo [99].
As shown in this chapter, an enormous amount of MSN designs and drug delivery strategies have
been developed. It is important, however, to constantly evaluate the efficiency of the newly developed
system on single cell level. To do so, fluorescence live-cell imaging is a powerful method as it allows
detailed insights into the individual processes in living cells.
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Fluorescence microscopy is based on recording of an emitted fluorescence signal in a microscope
setup within nanoseconds after light absorption. It can be used to gain important insight into key
questions in material science and biology, for example by exploring mesoporous silica structures
[192–196] or by studying virus entry and egress [197–199]. To study virus infection, functions of
biomolecules in cells, or general cell biological processes it is beneficial to perform fluorescence
microscopy on a single-cell level, so called live-cell imaging [200].
In this thesis, highly-sensitive fluorescence live-cell imaging of the uptake and intracellular trafficking
of CMS nanoparticles was performed. Our measurements enable direct observation of the dynamics
of nanoparticles and the route which a nanoparticle takes into and inside a living cell. This leads
to a detailed understanding of nanoparticle-cell interactions [201]. In addition, as we study CMS
nanoparticles as drug carrier, the drug release mechanism in cells and the cellular fate after drug
delivery can be studied in great detail. This knowledge can be a starting point for the development
of new drug delivery systems or improvement of existing nanocarriers.
In this chapter, an introduction into the principles of fluorescence and fluorescent dyes will be
given. Afterwards, loss of fluorescence by bleaching and quenching will be discussed theoretically.
This is of interest, as in practice, we took advantage of quenching for studies on nanoparticle
internalization kinetics and drug release. All our studies are made possible by high-end and custom-
built fluorescence microscopes. Therefore, an introduction into our wide-field and spinning disk
confocal microscope setups will be given. In a last part of this chapter, important developments
increasing the meaning of live-cell imaging will be shown. The contributions of live-cell imaging
adding information to standard ensemble measurements will be discussed.
4.1 Principles of fluorescence
Fluorescence is the emission of light by a molecule after absorption of a photon and energy transfer
from the photon to the absorbing molecule. To gain an overview of the photophysical processes
occurring in commonly used dyes, the Jablonski diagram conceived by Alexander Jablonski in the
1930s is adequate (see Figure 4.1).
When a fluorophore absorbs a photon, with sufficient energy generated by a laser or a lamp, it
will be excited from the ground state S0 to an electronic excited state Sn (n ≥ 1). Oftentimes,
the first electronic excited state S1 is populated in some higher vibrational level [203]. From this
state, the molecule can undergo vibrational relaxation to the lowest vibrational level of S1. During
vibrational relaxation the vibrational energy in the fluorophore is transferred to nearby molecules
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Figure 4.1: Jablonski diagram. Typical energy level scheme for fluorescence spectroscopy. Three elec-
tronic states are depicted: S0: ground singlet state, S1: first excited singlet state and T1: lowest triplet
state or other intermediate state. For each electronic states, vibrational energy levels (0, 1, 2, 3) are shown.
Excitation, fluorescence, phosphorescence, radiationless decays and vibrational relaxation processes are in-
dicated. Figure adapted from [202].
via direct interactions [202]. Vibrational relaxation occurs on a timescale of 10−12 s. From the lowest
vibrational level of S1, the electron is brought back to the ground state via fluorescence on a timescale
of 10−9 s or radiationless decay. In addition, vibrational relaxation might take place to reach the
lowest energy level of S0. The loss of energy by radiationless processes both in the excited and in
the ground state leads to an energy difference between excitation light and emitted light (Stokes
shift). The subsequently emitted light is typically of higher wavelength than the absorbed light.
This phenomenon renders fluorescence particularly powerful as the absorbed light can be separated
from the emitted light with appropriate filters such that only fluorescent objects are detected [202].
As an alternative to fluorescence emission, there is a certain probability that molecules undergo
spin conversion from the excited state to the first triplet state T1. This process, called intersystem
crossing, leads to electrons with parallel spins [202]. Some triplet-state molecules reach the ground
state without light emission (radiationless decay), others emit light shifted to longer wavelengths
relative to the fluorescence (phosphorescence). The latter process occurs on a timescale of 10−6 s or
longer. As the electron needs to reverse its spin, the transition is unlikely and forbidden by quantum
theory [202]. This leads to a slower decay than fluorescence.
To optimize the fluorescence signal, it is important to choose a fluorophore with suitable properties.
A fluorophore contains an atom or group of atoms that behave as a unit in light absorption such as
ketones, olefines, conjugated polyenes, conjugated enones and aromatic compounds [204]. Although
many organic substances have intrinsic fluorescence, oftentimes samples are tagged with organic
fluorescent dyes, nanocrystals (“quantum dots”), autofluorescent proteins, (fluorescently labeled)
genetically encoded tags, and combinations of these probes [205].
When choosing an appropriate fluorophore its quantum yield and photostability play an important
role. The fluorescence quantum yield (Q) is defined as the average ratio of emitted photons to the
average number of photons absorbed. A high fluorescence quantum yield close to 100% is desirable
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[206]. The quantum yield (Q) and fluorescence lifetime (τ0) of a fluorophore are governed by the
radiative decay rate (Γ) and the sum of the non-radiative decay rates (knr) connected to transitions
from the excited state to the ground state [203].
Q = Γ · τ0 = ΓΓ + knr (4.1.1)
The fluorescence lifetime is defined as the average time the molecule stays in its excited state prior
to returning to the ground state and is generally in the range of nanoseconds [203]. High quantum
yields and short lifetimes are characteristic for fluorophores with high radiative rates [207]. Another
important property of a fluorophore is its photostability. It should ideally be high, as almost all
fluorophores are photobleached at some point upon continuous illumination [203].
4.2 Bleaching and quenching
The outcome of photobleaching is permanent fading of the fluorescent signal after a limited number
of cycles between ground and excited states [202]. Photobleaching is dependent on the fluorophore
structure and local chemical environment and is thought to be associated with photo-oxidation or
other reactive degradation processes of the molecule.
Another effect that leads to a loss of fluorescence signal is called quenching. In contrast to pho-
tobleaching, this loss in fluorescence is reversible. Quenching is caused by noncovalent interac-
tions between a fluorophore and its molecular milieu [202]. Two mechanisms are proposed: Colli-
sional/dynamic quenching and static quenching. Collisional quenching occurs on the level of the
excited fluorophore. Static quenching involves the ground-state fluorophore associating with an-
other molecule. If the other fluorophore is identical, so-called self-quenching occurs [202]. However,
although fluorescence quenching is a well-established technique, the mechanism of the quenching
reaction is often not known with certainty [208].
4.3 Wide-field and spinning disk confocal microscopy
In this work, two microscopy techniques have been used: wide-field and spinning disk confocal mi-
croscopy. In wide-field microscopy a large area of interest is illuminated by a laser or an arc lamp
and the fluorescence of this entire field of view is collected [209]. Laser illumination is beneficial as it
provides high excitation intensities that are essential for strong photon emission by the fluorophores
[201]. An epi-fluorescence microscope modified for wide-field laser illumination and equipped with
two highly-sensitive EMCCD cameras was used. The wide-field setup is shown schematically in
Figure 4.2a. For excitation of the sample, three lasers (405, 488 and 640 nm) are used. Their beams
are aligned and guided into an acousto-optical tunable filter (AOTF) for adjusting the transmission
intensities and combining the individual laser beams. Subsequently, the beam is coupled into an
optical fiber, sent through a beam expander and focused on the back focal plane of the objective to
achieve wide-field illumination. The laser beam exits the objective and excites the sample. Fluores-
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Figure 4.2: Wide-field and spinning disk confocal microscope setups. (a) In the wide-field setup,
the lasers are focused onto the back focal plane of the objective for excitation of the sample. The fluorescence
of the sample is collected by the objective and separated into two spectrally-separated channels. The
fluorescence signal was projected onto two EMCCD cameras. The setup is based on the Nikon Eclipse Ti.
(b) In the spinning disk setup, the laser light enters the spinning disc head and is further directed to the
microscope to illuminate the sample. The emitted fluorescence passes the spinning disc head and is guided to
the optosplit. The spectrally separated signal is imaged onto the two channels of the EMCCD camera. The
setup is based on the Nikon 2000E. Adapted from figures provided by the courtesy of Dr. Sergey Ivanchenko
and Dr. Yoshihiko Katayama.
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cence light is collected from the sample by the objective in epifluorescence mode and separated from
the excitation light by a dichroic mirror. The fluorescent light is further split by a dichroic mirror
and two band-pass filters into two spectrally different channels that are imaged onto two separate
EMCCD cameras.
The images or movies obtained with a wide-field system contain out-of-focus background signal and
are two-dimensional. To extend the information from 2D (x- and y dimension) to 3D (z-dimension),
the sample has to be scanned in the third dimension. This has been performed in this work by
spinning disk confocal microscopy.
A spinning disk microscope is based on a so-called spinning disk unit where fast rotating discs contain
concentrically arranged, multiple lenses and pinholes allowing for multiple scans simultaneously. By
screening the many confocal spots over the sample an image is created. This allows to collect
the image faster than scanning confocal microscopy and with multiple images per second. However,
powerful lasers are required since the pinhole passes only a small amount of light [210]. The spinning
disk microscope used for this work is commercially available from Andor technology and is depicted
schematically in Figure 4.2b. The excitation path consists of three lasers (488, 561 and 635 nm with
50 mW) that can be selectively chosen in desired combinations by utilizing an AOTF. The lasers
are coupled into a single-mode optical fiber and directed into the spinning disk unit. Afterwards,
the beam passes the fast rotating microlense and pinhole disks, before entering the microscope and
passing through the objective for illumination of the sample. The sample position is controlled in
its x- and y-position by a motorized stage and in the z-position by a piezo-stage. In the fluorescence
emission path, the fluorescence passes the pinhole disk for rejection of signal from outside the
objective focal plane. Afterwards, emission light is spectrally separated from the excitation light by
a quadruple dichroic mirror. A filter cube with an appropriate dichroic mirror and filters separates
the emission light on two different parts onto the EMCCD camera.
Wide-field and spinning disk microscopy are highly sensitive fluorescence techniques and can be
used for live-cell imaging to elucidate the details of nanoparticle–cell interactions on the single-cell
level with high temporal and spatial resolution in real-time [201].
4.4 Living cancer cells in fluorescence microscopy
To non-invasively image a cell in all its dimensions, fluorescence microscopy is a powerful method
[211]. For cell imaging, good excitation wavelengths are typically in the range of visible light.
However, for in vivo imaging in an organism, the optimal excitation wavelength of a fluorophore is
in the deep red or near-infrared range, because of the combined virtues of good tissue penetration
due to a reduced tissue absorption in the range of 800 - 1200 nm [84], and low autofluorescence [212].
A breakthrough in the field of fluorescence live-cell imaging was the discovery and development of
the green fluorescent protein (GFP and the related fluorescent proteins such as YFP and RFP)
that led to the Nobel Prize in Chemistry for O. Shimomura, M. Chalfie and R.Y. Tsien in the year
2008. With fluorescent proteins, such as GFP, proteins of live cells can be permanently labeled
with multiple colors. This is achieved by fusing the desired host cell gene to the genes of the
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protein(s) of interest [213]. In a second step, the fusion construct is introduced into the cell, where
the fusion protein is stably expressed. The ability to specifically and stably label desired cellular
components enables dynamic insights into cellular processes that are not obtainable with fixed cells
[214]. As one example, cancer research profited from tumor cells stably-expressing GFP and other
fluorescent proteins in vivo by the possibility to examine tumor cell mobility, invasion, metastasis
and angiogenesis [215]. In our work, we used HuH7 cells stably expressing GFP fluorescently-
labeled cytoskeletal elements, such as actin and tubulin. The success of drug delivery was shown by
incubation of cells containing GFP-labeled actin or tubulin with CMS loaded with drugs directed
against actin or tubulin or their GFP-label. With this system, the outcome of drug delivery was
assessed. Another set of experiments involved dynamics of fluorescently labeled nanoparticles with
living cells. To examine the dynamics, we used single-particle measurements in living cells. Single-
particle measurements can give insights into the position or movement of the fluorescent particles,
the fluorescence intensity of the individual spots, as well as the color, the number, and distribution
of the spots [216]. With all these information one can already draw conclusions on single-particle
interactions with living cells. One advantage of single-particle imaging on the single-cell level is that
distributions and fluctuations as well as “rare events” can be detected, which adds to the information
available by ensemble measurements. Ensemble measurements (gene expression or flow cytometry)
can investigate the final outcome, whereas high-resolution live-cell imaging provides detailed kinetic
information on uptake and intracellular trafficking and spots bottlenecks in a chain of succeeding
events [201].
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5.1 Chemicals
The following chemical were used as received without further purification: 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), dioleoyl-phosphatidylethanolamine (DOPE), dioleoyl-sn-glycero-3-phospho-
choline (DOPC), dioleoyl-trimethylammonium propane (DOTAP), didodecyldimethylammonium
bromide (DDAB, all purchased from Avanti Polar Lipids), cetyltrimethylammonium bromide (CTAB,
Fluka), Alexa Fluor 488 (AF488) and Alexa Fluor 488 Dextran (AFD, MW 10 kDa, both Invitrogen),
cell culture media, fetal calf serum and B-27 serum-free supplement (Invitrogen), L-glutathione re-
duced (GSH, Sigma-Aldrich), meso-tetraphenylporphine (TPPS2a, LumiTrans®, PCI Biotech), col-
lagen A (Biochrom AG), 0.4% trypan blue solution and fluorescein sodium salt (Sigma). ATTO594
and Chromeo642-labeled chromobodies were provided by Dr. Ulrich Rothbauer (chromotek). Dou-
bly distilled water from a Millipore system (Milli-Q Academic A10) was used.
5.2 Cell culture
HeLa cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) with Glutamax I. Wild-
type, actin-GFP and tubulin-GFP expressing HuH7 cells were grown in DMEM:F12 (1:1) at 37°C
in 5% CO2-humidified atmosphere. All media were supplemented with 10% fetal calf serum. To
reduce autofluorescence in case of the HuH7 cells, the medium was changed to DMEM:F12 sup-
plemented with 10% B-27 two days before seeding. The cells were plated on collagen A-coated
LabTek-chambered cover glass (Nunc) 1-3 days before the measurement or incubation with the
CMS nanoparticles in densities of 0.75× 104 cells/cm2 to 2× 104 cells/cm2. Prior to imaging, the
medium was changed towards CO2-independent medium (Invitrogen) and the cells were kept on
a heated microscope stage at 37°C. There are two ways of nanoparticle incubation with cells. In
case of short-term incubations (t < 2 h), the nanoparticles were pipetted into the CO2-independent
medium used for the measurements and the cells were incubated with the nanoparticles on the
heated microscope stage. In case of long-term incubations (t > 2 h), the nanoparticles were added
to the DMEM:F12 (1:1) medium (for HeLa cells) or DMEM:F12 supplemented with 10% B-27 (for
HuH7 cells) and incubated at 37°C in 5% CO2-humidified atmosphere prior to imaging.
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5.3 Preparation of SLB@CMS
In a first step, the lipids have been prepared by Dr. Hanna Engelke from the group of Prof. Joachim
Rädler. POPC, DOPC, DOPE, DOTAP and DDAB in various mixtures of given molar proportions
were used. To obtain labeled SLBs, the amount of 2.5 mg of the lipids in chloroform was mixed
with BODIPY-labeled HPC-lipids (0.5 µg), respectively. Chloroform was evaporated and the lipids
were dried under vacuum overnight. Then the lipids were dissolved in a 1 mL mixture of 40%vol
ethanol/60%vol water to yield a concentration of 2.5 mg/mL.
The lipids were then used for formation of the SLB. For this, the amount of 1 mg of CMS nanoparti-
cles (25 mg/mL in EtOH) unlabeled or labeled with ATTO633 were centrifuged (19.000 rpm, 30 min)
and 100 µL of unlabeled or labeled lipids (2.5 mg/mL in a mixture of 40%vol EtOH/60%vol water)
were added. Upon addition of 700 µL of water, the formation of SLB on the external surface of CMS
was induced. The SLB@CMS were then centrifuged again and redispersed in 800 µL of water, to
eliminate unsupported lipids and the ethanol.
5.4 Fluorescence spectrometry
Spectrometry of trypan blue-based dye quenching
Emission spectra of the dyes AF488, ATTO488 and FITC were recorded in water with an excitation
at 488 nm, emission spectra of Cy3 in water were recorded at 532 nm excitation on a FS900 fluo-
rescence spectrometer (Edinburg Instruments). All spectra were recorded under exactly the same
conditions with the same scan speed and step width (0.5 nm).
In-vitro release experiment from SLB@CMS.
The amount of 1 mg of unlabeled CMS nanoparticles (25 mg/mL in EtOH) was added to 10 mL of
an aqueous solution of fluorescein sodium salt (1 µM, Sigma) and stirred (500 rpm) for 1 h at RT in
the dark. In the case of colchicine, 1 mg of CMS nanoparticles labeled with ATTO633 was combined
with 50µL of an aqueous solution of colchicine (25 mM, Sigma) for 3 h under stirring at RT. After
centrifugation, 100 µL of unlabeled lipids (2.5 mg/mL in a mixture of 40%vol EtOH/60%vol water)
and 700 mL of water were added. The SLB@CMS were then centrifuged twice and redispersed in
800 µL of water, to eliminate the unsupported lipids and free dye molecules. Fluorescein-loaded
CMS nanoparticles without lipids were prepared similarly as reference samples. An amount of
200 µL of the aqueous suspension containing SLB@CMS loaded with fluorescein or colchicine and
loaded CMS nanoparticles without lipids, as reference samples, was transferred into a tube which
could be closed by a holey cap lined with a dialysis membrane (with a molecular-weight cutoff
of 16.000 g/mol). This custom-made system fits on the opening of a fluorescence cuvette, filled
with 3 mL water. Whereas the SLB@CMS or CMS nanoparticles are too large to diffuse through
the dialysis membrane, the dye molecules can enter the free cuvette volume and are detected by
fluorescence spectroscopy. For the fluorescein delivery experiment, the excitation wavelength was
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490 nm and the expected fluorescence emission maximum is 512 nm. Colchicine excited at 380 nm
shows a maximum of emission at 437 nm. The dye-loaded SLB@CMS was monitored up to 60 min.
After the addition of 20µL of absolute EtOH or Triton X-100 (Sigma) into the tube containing the
SLB@CMS sample, the lysis of the lipids from the CMS nanoparticles allows the diffusion of the
dye molecules out of the mesopores and their detection in the cuvette.
5.5 Microscopy in vitro and in live cells
Trypan blue-based nanoparticle quenching
In case of the control measurements, Cy3-labeled CMS-PEG550 and 5000 MW nanoparticles were
sedimented on LabTek-chambered cover glass (Nunc) and exposed to 0.04 g/L trypan blue (Sigma) in
CO2-independent cell culture medium (Invitrogen). For the quenching measurements in live cells,
Cy3-labeled CMS-PEG550 nanoparticles were added to HeLa cells growing on collage A-coated
LabTek-chambered cover glass (Nunc). After 10-80 min of nanoparticle incubation, the cells were
exposed to 0.04 g/L trypan blue. In both cases, the fluorescence intensity was recorded before and
after trypan blue addition on a fluorescence wide-field microscope. The amount of particles before
and after quenching was determined by a Labview-based application “Count Co-localization” by
Volodymyr Kudryavtsev (group of Prof. Christoph Bräuchle, Prof. Jens Michaelis and Prof. Don
Lamb, all LMU). First, a threshold for the fluorescence intensity of a single particle was determined
by multiple measurements of the particles on cover glass. Is the fluorescence of a particle above
the threshold, it is counted by the program. The particles showing a fluorescence lower than the
threshold are determined as quenched and not counted. Comparison of the amount of nanoparticles
counted before and after quenching gives the percentage of internalization into the cells.
Dye release at single-particle level on glass.
Redox-cleavable CMS-CysATTO633core and the non-cleavable control CMS-ATTO633core were mea-
sured on glass on a wide-field fluorescence microscope first in water, then in 10 mM GSH solution.
Movies of the ATTO633 and background fluorescence were recorded before (t < 0 min) and af-
ter (t > 0 min) addition of the GSH solution. As a control measurement, redox-cleavable CMS-
CysATTO633core nanoparticles were measured on glass in 0.025 µg/mL TPPS2a solution. The flu-
orescence intensity of the particles was measured before and after activation with laser light of
405 nm.
Photochemical endosomal release of CMS nanoparticles by TPPS2a.
The photochemical release experiments were performed on the basis of the experiments by de Bruin
et al. [30]. In brief, the cells were seeded at a density of 0.75× 104 cells/cm2, 3-4 days before
imaging. 12-24 hours before imaging, the medium was replaced by a medium containing 0.025 µg/mL
TPPS2a. AFD in a concentration of 0.24 mg/ml and the nanoparticles were added to the cells. Cells
were incubated overnight, washed three times with CO2-independent medium and subsequently
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transferred to a 37°C heated microscope stage. The photosensitizer was activated by illumination
with 405 nm laser light for 1 min. After the activation of the photosensitizer, the measurement was
performed with alternating excitation by 488 and 642 nm laser light.
Photochemical drug delivery from CMS nanoparticles by covalently
surface-bound PpIX.
The cells were seeded at a density of 0.75× 104 cells/cm2, 3-4 days before imaging. 12-24 hours
before imaging, PpIX-CMS nanoparticles were added to the cells in culture together with AFD
in a concentration of 0.24 mg/ml. Cells were incubated overnight, washed three times with CO2-
independent medium (Invitrogen) and subsequently transferred to a 37°C heated microscope stage.
The photosensitizer was activated by illumination with 405 nm laser light for 1 min. After the
activation of the photosensitizer, the measurement was performed with alternating excitation by
488 and 642 nm laser light.
Wide-field fluorescence microscopy for live-cell imaging.
Wide-field fluorescence microscopy was performed on a custom-built setup based on the Nikon
Ti microscope equipped with a 1.45 N.A. 60x Apo TIRF oil immersion objective (Nikon). The
photosensitizer was excited by 405 nm laser light (~0.15 W/cm2) 15 s-1 min prior to imaging. AFD
and ATTO594/ATTO633 were excited by 488 and 561 or 642 nm laser light in alternating fashion.
Fluorescence was collected in epifluorescence mode, split into two emission channels by a dichroic
mirror (565 DCXR, Chroma) and passed through adequate filter sets (525/50, 617/73 or 725/150,
Semrock). The green and red emission channels were projected onto two EMCCD cameras (iXon+,
Andor Technology) with a pixel format of 512x512. The presented overlays of the the two camera
channels were made afterwards.
Spinning disk confocal microscopy for live-cell imaging
Confocal microscopy for live-cell imaging was performed on a spinning disk confocal microscope
purchased from Andor (Revolution System). The setup is based on the Nikon TE2000E and uti-
lizes a Yokogawa spinning disk unit (CSU10). The system was equipped with a 1.49 NA 100x Plan
Apo oil immersion or a 1.3 NA 40x Plan Fluor oil immersion objective from Nikon. Samples were
illuminated with 488 nm, 561 nm and 640 nm lasers exciting GFP, BODIPY, ATTO488, PI and
Alexa Fluor 647 or Chromeo642 and ATTO633 respectively. For two-color detection of ATTO488
and ATTO633, dichroic mirrors and band-pass filters HQ 525/50 and 730/140 were used (AHF
analysentechnik AG). The same settings were used for two-color detection of GFP and Alexa Fluor
647 or Chromeo642, as well as for two-color detection of GFP or BODIPY and ATTO633. For the
detection of PI a 585 nm dichroic mirror and 630 /69 nm filter was employed. Image sequences were
captured on two different sections of an electron multiplying charge coupled device camera (iXon+,
Andor Technology) with a pixel format of 512x512. The presented overlays of the different sections
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and z-planes were made afterwards.
5.6 Fluorescence intensity evaluation of the CMS-loaded drug
and fluid phase marker.
The fluorescence intensity of nanoparticles was obtained by calculating the mean fluorescence in-
tensity of regions of interest (ROI) containing a single endosome or nanoparticle for all frames of a
movie. To account for different laser excitation intensities and differing fluorescence intensities of
individual movies, the mean fluorescence intensity was normalized to the initial background intensity
defined by a ROI in a region without particles and plotted over time.
In some cases, as stated in the text, a rolling ball background filter of 5 pix was used to remove
inhomogeneous background fluorescence due to released AFD and loaded drugs in both channels
[217]. Afterwards, the mean fluorescence intensity was normalized to the highest intensity value and
plotted versus time.
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6 Internalization of CMS nanoparticles
Nanoparticles for intracellular drug delivery have to cross several barriers in a human body before
they deliver their drug cargo to the site of action. One important site of action for drug delivery is
the cellular cytoplasm. In cytoplasmic drug delivery, the first major barrier for the nanoparticle on
the cellular level is the plasma membrane of the target cell. Therefore, processes occurring during
the initial contact of the nanoparticle with the plasma membrane that result in the intracellular
presence of the nanoparticle are of great importance. One way to study the cellular entry is to
explore the internalization time scale of nanoparticles. The nanoparticles used for this study are
CMS nanoparticles with a polyethylene glycol (PEG)-shell. PEG coatings are particularly important
for intravenously administered drug carriers due to their shielding capability, leading to reduced
plasma protein adsorption and reduced phagocytosis by cells of the reticulo endothelial system
(RES) [23, 218]. Thus, the PEG shell increases the nanoparticle’s lifetime in blood circulation
and avoids capturing of the nanoparticles before reaching the target cell [11]. However, despite
the advantages, PEGylation reduces cellular uptake and slows down the internalization dynamics
[1, 218]. To increase the specificity of cellular binding and to speed up internalization, targeting
moieties can be attached to the surface of the nanoparticles. The so-called “targeting” leads to
specific receptor-ligand interactions of nanoparticles with the cell and overcomes the problem of low
and unspecific interactions of PEG-shielded nanoparticles [218].
In this chapter, we examine the internalization time scale of PEG-shielded CMS nanoparticles into
living HeLa cells by a quenching assay. The assay exploits the fact that a cell membrane-impermeable
quencher dye only quenches extracellular particle fluorescence, whereas the intracellular particles
remain visible. Comparing the amount of fluorescent spots visible before and after quencher addition,
the percentage of internalized nanoparticles can be evaluated. However, before the quenching assay
could be performed, the experimental conditions had to be optimized. In a first step, we tested
different dyes for their ability to be quenched by trypan blue, a well-known membrane-impermeable
quencher dye. In a second step, PEGylated CMS nanoparticles containing PEG chains of different
molecular weights have been evaluated as quenchable nanoparticles. Finally, after the measurement
conditions were set, the quenching assay was performed on a single-cell level. In the last part of this
chapter, first attempts for CMS targeting to cancer cells will be presented as an outlook to future
work.
6.1 Choice of a quenchable dye
For the quenching assay on living cells, a dye is needed that is quenched well by the cell membrane-
impermeable quencher dye trypan blue. To find a dye suitable for this experiment, we recorded
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Figure 6.1: Fluorescence spectra of fluorophores quenched by trypan blue. Fluorescence spectra
of four dyes in aqueous solution were taken upon addition of trypan blue in different concentrations (black
curves: spectra without trypan blue, blue curves: 0.01 g/L trypan blue and gray curves: 0.06 g/L trypan
blue.) (a) AF488 is not well quenched by trypan blue in the applied concentration range. (b) ATTO488
is slightly quenched by trypan blue. (c) FITC shows a more pronounced ability to be quenched by trypan
blue. (d) Cy3 is quenched well already at a trypan blue concentration of 0.01 g/L.
emission spectra of Alexa Fluor 488 (AF488), ATTO488, fluorescein isothiocyanate (FITC) and
Cy3 in the absence and presence of trypan blue by fluorescence spectrometry. All dyes, except for
ATTO488, have been reported to be quenched by trypan blue in cellular uptake studies [1, 219, 220].
However, the concentration of trypan blue varied considerably between the different studies. From
previous studies in our lab, we know that the trypan blue concentration should be around 0.04 g/L
[1, 2]. Higher concentrations result in a high fluorescence background signal due to the fluorescence
of trypan blue itself. Therefore, we wanted to investigate the ability of the aforementioned dyes to
be quenched by trypan blue in concentrations of 0.01 g/L and 0.06 g/L. For the measurement, the
dyes were diluted in water and added to a 200 µL cuvette. Emission spectra of AF488, ATTO488
and FITC were recorded at an excitation of 488 nm on a fluorescence spectrometer. In case of Cy3
an excitation wavelength of 532 nm was used. The emission intensities were normalized and are
presented in Figure 6.1.
Depending on the dye, the quenching effect is found more or less pronounced. Starting from their
initial fluorescence intensity curves without trypan blue (depicted in black in Figure 6.1a and b),
AF488 and ATTO488 show almost no reduction in their fluorescence intensity upon addition of
0.01 g/L trypan blue (blue curves in Figure 6.1a and b). Further addition of trypan blue up to a
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Figure 6.2: Synthesis scheme of CMS-PEG nanoparticles. A triethoxy-silane terminated PEG-
precursor is used for co-condensation with the silica precursor. This approach is used to bind the PEG
precursor covalently to the outer surface of the growing CMS nanoparticles. In a last step, the CMS surface
is labeled with the fluorescent dye Cy3. Adapted from a figure provided by the courtesy of Christian Argyo.
concentration of 0.06 g/L decreased the fluorescence intensity slightly in case of AF488 (gray curve
in Figure 6.1a) or more pronounced in case of ATTO488 (gray curve in Figure 6.1b). However, a
significant reduction can be observed in case of FITC (Figure 6.1c) and Cy5 (Figure 6.1d), with
complete quenching at a trypan blue concentration of 0.01 g/L. For this reason, Cy5 was selected
to be bound to the nanoparticle surface and is used for the following studies.
6.2 Choice of quenchable CMS nanoparticles with PEG-shell
To design nanoparticles for quenching experiments, CMS with surface-bound Cy3 and PEG shells
have been synthesized by Christian Argyo from the group of Prof. Thomas Bein. PEGylation is
beneficial as the nanoparticles show enhanced colloidal stability in aqueous suspensions when PEG
polymer is grafted on the nanoparticle’s surface [221]. Well-dispersed, unaggregated nanoparticles
are in turn a prerequisite for a successful evaluation of the quenching assay.
A schematic representation of the synthesis is depicted in Figure 6.2. As a first step, a linear
PEG-silane precursor is synthesized and added to the CMS synthesis mixture for outer shell func-
tionalization with linear PEG-silanes using a delayed co-condensation approach [9]. Finally, the
silica surface is labeled with Cy3 by reacting the dye’s NHS ester group with the residual amino-
propyl functionality derived from the co-condensation approach with unpurified PEG-aminopropyl
silane precursor (see Figure 6.2). Unreacted dye is washed away with ethanol and the nanoparti-
cles are dispersed in water (for details see [222]). Two particle types were synthesized: CMS with
PEG550 and 5000 MW. The particle types have been tested for their ability to be quenched by
trypan blue.
To test the ability of the Cy3-labeled CMS nanoparticles with PEG550 and 5000 MW shells to be
quenched by trypan blue, the nanoparticles in aqueous suspension have been sedimented on glass
coverslips. The fluorescence of the Cy3-labeled nanoparticles was recorded in a movie sequence
before and after addition of 0.04 g/L trypan blue. The fluorescence intensities of four representative
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Figure 6.3: Quenching of CMS-PEG nanoparticles. Fluorescence intensity plots of four representa-
tive nanoparticles on cover glass. (a) Cy3-labeled CMS with PEG 550MW before (t = 0 − 10 s) and after
trypan blue addition (t = 25 − 45 s). (b) Cy3-labeled CMS with PEG 5000MW before (t = 0 − 20 s) and
after trypan blue addition (t = 45 − 80 s). A PEG layer composed of 550MW PEG was found to be more
permeable for trypan blue than one composed of 5000MW PEG.
nanoparticles were extracted, normalized and plotted versus time (see Figure 6.3). In the evaluation,
nanoparticles are counted as successfully quenched if two prerequisites apply. First, all nanoparticles
on cover glass have to decrease in their fluorescence intensity. Second, it is possible to set a clear
threshold between the fluorescence intensity of unquenched and quenched nanoparticles. CMS-
PEG550 nanoparticles show a decrease of their fluorescence intensity after trypan blue addition (see
Figure 6.3a). A clear threshold can be set between the fluorescence intensity of the nanoparticles
before and after quenching. This result indicates that the PEG550 shell enables trypan blue to
reach the Cy3 dyes on the CMS nanoparticle surface. CMS-PEG5000 nanoparticles, however, show
a slight reduction in fluorescence intensity that is not sufficiently high to set a threshold between
the fluorescence intensity before and after trypan blue addition (see Figure 6.3b). Therefore, CMS-
PEG550 nanoparticles were chosen for subsequent uptake studies on HeLa cells.
6.3 Uptake percentage of CMS-PEG550 into HeLa cells
To determine the timescale of internalization of Cy3-labeled CMS-PEG550 nanoparticles into HeLa
cells, quenching experiments were performed with trypan blue. Addition of trypan blue to the cells
leads to quenching and disappearance of the Cy3-fluorescence of extracellular nanoparticles, the
fluorescence of intracellular particles remains intact. Before and after application of trypan blue,
the Cy3-CMS-PEG550 fluorescence was recorded in an image sequence on a wide-field microscope.
From the movie, the amount of fluorescent spots before and after trypan blue addition is compared
and the percentage of internalized nanoparticles can be determined (for a detailed description, see
[30]). For the experiment, the nanoparticles have been incubated with HeLa cells for 10-80 min.
Quencher dye addition occurred at different time points within this time range.
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Figure 6.4: Quenching experiments on HeLa cells to determine the percentage of internalized
CMS-PEG550 nanoparticles at different timepoints. (a) Fluorescence wide-field image of CMS-
PEG550 nanoparticles (highlighted by white boxes) incubated for 55min with a HeLa cell before addition
of trypan blue. (b) Fluorescence image of the cell after addition of trypan blue. Two particles are still
visible after trypan blue addition. The nucleus and the cell boundaries are outlined in white. Scale bar:
5 µm. (c) Internalization kinetics of CMS nanoparticles into cells measured by particle quenching. The plot
displays the percentage of internalized nanoparticles determined at different time points after addition of
the nanoparticles to the cells. Each data point in the graph represents one single-cell measurement.
Figure 6.4a and b show the fluorescence images of Cy3-labeled CMS-PEG550 nanoparticles incu-
bated with a HeLa cell for 55 min. Before trypan blue addition, six nanoparticles are counted in the
cellular region (white boxes), as determined by transmitted light image and indicated by white lines
(see Figure 6.4a). After trypan blue addition two nanoparticles were counted (see Figure 6.4b). As
a result, 33% of the nanoparticles have been internalized into the cell after 55 min. 77% were still
quenchable and therefore present in the cell exterior. The data obtained by quenching of 38 different
HeLa cells is plotted in Figure 6.4c. The percentages of internalized CMS-PEG550 nanoparticles
after different incubation time intervals are shown. Since quenching was irreversible, each data point
in the graph represents one single-cell measurement. The nanoparticles exhibit a large spread in the
internalization time. After 20 min 22% (median value) of the particles were internalized by HeLa
cells. This percentage increases with time to 67% after 60 min. The internalization percentages are
in the same range as obtained for PEI polyplexes and magnetic lipoplexes in HuH7 liver cancer cells
[1, 2]. This is not surprising, as all three particle types lack a receptor ligand as targeting moiety.
Therefore, non-specific uptake and thus a similar internalization time scale may be expected. Par-
ticles with specific receptor targeting unit, such as EGF-targeted polyplexes, show a much faster
internalization behavior with 50% (median) internalization after 5 min and 91% (median) internal-
ization after 10 min [1]. It can be noted that epidermal growth factor receptor (EGFR) targeting
leads to fast and efficient internalization.
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6.4 Targeting of CMS nanoparticles with receptor-ligands
Current efforts to improve the internalization of CMS nanoparticles focus on ligands for cancer cell
targeting. In first preliminary studies, Dr. Axel Schlossbauer, Dr. Valentina Cauda and Christian
Argyo, from the group of Prof. Thomas Bein, equipped CMS nanoparticles with receptor ligands
for fast intracellular uptake and, above all, for cancer specific targeting. One targeting ligand is
the epidermal growth factor (EGF), a globular protein of 6.2 kDa consisting of 53 amino acids,
that binds specifically and with high affinity [223] to the epidermal growth factor receptor (EGFR,
Her1, ErbB1). The receptor plays a role in the control of proliferation, differentiation, and cell
survival and is overexpressed on multiple solid tumors [224]. In first experiments, EGF was bound
directly to the CMS surface without a PEG spacer. However, this leads to aggregation of the EGF-
equipped nanoparticles. The particles were not applicable for uptake and single-particle tracking
studies. Ongoing research by Christian Argyo (group of Prof. Thomas Bein) and Veronika Weiß
(group of Prof. Christoph Bräuchle) focuses on EGF-receptor targeting by EGF-equipped CMS
nanoparticles. The CMS particles are coated by a lipid bilayer and EGF is attached to a DSPE-
PEG linker incorporated in the lipid bilayer.
6.5 Summary
In this chapter, a quenching assay was prepared and performed to assess the internalization time
scale of PEG-shielded CMS nanoparticles into living HeLa cells. As a first step for the preparation of
the quenching assay, we evaluated the ability of dyes to be quenched by trypan blue. The emission
spectra of AF488, ATTO488, FITC and Cy3 before and after addition of trypan blue revealed
that Cy3 is a well-suited dye for our purposes. As a second step, Cy3-labeled CMS nanoparticles
containing PEG shells of 550 and 5000 MW have been tested for their ability to be quenched by
trypan blue by fluorescence microscopy. CMS-PEG550 nanoparticles showed a reduction of the
fluorescence intensity after quenching. An intensity threshold to distinguish between the unquenched
and the quenched state was set. Therefore, CMS-PEG550 fulfilled the criteria for the quenching
assay. To perform the quenching assay and determine the internalization time scale of CMS into
living HeLa cells, Cy3-labeled CMS-PEG550 nanoparticles were used. As expected, a large spread
of the internalization times was observed. After 20 min 22% (median value) of the particles were
internalized into the cells. The percentage increased with time up to 67% after 60 min. The time
scale is similar to other nanoparticles exhibiting non-specific uptake. To speed up the internalization,
first preliminary experiments have been performed with EGF-equipped CMS nanoparticles. Future
research will focus on this important subject.
In summary, the internalization time scale of PEG-shielded CMS nanoparticles resembles other
unspecifically internalized nanoparticles. With this in mind, we focused on further parameters
that are important for successful drug delivery, such as drug loading, pore sealing and intracellular
controlled release.
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For the delivery of therapeutic substances to diseased cells by mesoporous silica nanoparticles,
drug loading and intact sealing of the pores is essential to prevent degradation or premature drug
release. A variety of strategies for pore sealing have been reported, including large molecules,
clusters or molecular assemblies [129, 140, 156, 225] (see Chaper 3.3.2). An alternative design
involves supported lipid bilayers (SLB) that cover the entire surface of the particles [143, 144, 226].
Lipid bilayers, as main components of cellular membranes, have been studied especially in form
of liposomes as drug and gene delivery vehicles. Liposomes are advantageous systems, due to
the amphiphilic nature and good biocompatibility profile [23]. However, besides their advantages,
liposomes have the disadvantage of low structural stability [143]. Therefore, we applied lipid bilayers
on CMS nanoparticles as solid support and stabilized the bilayer while efficiently closing the pores.
In the first part of this chapter, SLB-coated CMS will be studied as drug carrier for the anti-
cancer drug colchicine. The particles have been synthesized, loaded with the drug and sealed by the
lipid bilayer. Bulk delivery kinetics of a dye from SLB@CMS have been measured by fluorescence
spectrometry. Spinning disk confocal live-cell imaging of colchicine-loaded SLB@CMS has been
performed to gain insight into the drug delivery mechanism in living cancer cells (Chapter 7.1).
This chapter is taken in parts from our publication in Nano Letters [12].
In the second part of this chapter, the mode of cellular uptake of lipid bilayer-coated CMS will be
studied depending on the composition of the lipid bilayer. The composition of the lipid bilayer plays
an important role for interaction of the system with other membranes [227] and therefore also for
cellular uptake. The predominant mode of uptake of CMS nanoparticles into cells is endocytosis.
However, besides endocytosis, fusion with the plasma membrane could be of interest. Possible
advantages of fusion include that endo/lysosomal entrapment is avoided and that the lipid bilayer-
seal covering the nanoparticle remains in the plasma membrane while the particle enters the cytosol.
Some enveloped viruses, for example, optimized their lipid bilayer composition such that fusion of the
bilayer with the plasma membrane is one pathway for cellular entry. Therefore, we synthesized lipid
bilayers of various compositions, incubated them with HuH7 cells and examined by live-cell imaging
and co-localization analysis, whether a separation of SLB from CMS due to fusion is observed after
internalization (Chapter 7.2).
7.1 Colchicine delivery by lipid bilayer-coated CMS
To coat CMS by lipid bilayers, different strategies have been pursued. In first studies by Prof.
Brinker and co-workers lipid coating was achieved by fusion of positively charged liposomes with
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Figure 7.1: Scheme of the synthetic procedure for the formation of SLB on CMS nanoparticles.
(a) The lipids in chloroform were mixed with dye-labeled lipids. After chloroform evaporation, the mixture
of unlabeled and labeled lipids was desiccated and redispersed in a mixture of 40%vol EtOH/60%vol water.
(b) After the synthesis of outer surface amino-functionalized CMS, the amino-propyl groups were labeled
with a fluorescent dye. The labeled particles were then centrifuged. (c) The lipid solution was added to the
centrifuged dye-labeled CMS nanoparticles. Upon addition of water, the SLB was formed on the surface of
the CMS nanoparticles. (d) The two kinds of lipids used are DOPC and POPC.
negatively charged mesoporous silica nanoparticles [143]. The composition of the nanoparticle-
supported liposomes was further modified by lipid exchange with free liposomes. The synthesis
yielded 100 nm lipid-coated mesoporous nanoparticles retaining 75% of a loaded dye. In addition,
doxorubicine delivery to living CHO cells was shown [144]. However, there is a lack of detailed
studies on the drug delivery properties of these particles on a single-cell level.
In our study, a solvent-exchange method was used to obtain single CMS nanoparticles coated with
an intact SLB. In addition, we studied in detail the drug delivery properties of this particles by
live-cell imaging. The data presented in this chapter have been published in Nano Letters [12]. The
supported lipid bilayer-coated CMS nanoparticles (SLB@CMS) were developed in a close collabo-
ration with Dr. Valentina Cauda of the group of Prof. Thomas Bein and Dr. Hanna Engelke and
Dr. Delphine Arcizet of the group of Prof. Joachim Rädler (both LMU Munich).
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Figure 7.2: Fluorescence spec-
trometry of fluorescein deliv-
ery kinetics from SLB@CMS.
Fluorescein-loaded CMS nanopar-
ticles without SLB release fluores-
cein within 10min into the sur-
rounding medium (see blue curve).
Fluorescein loaded SLB@CMS do
not show fluorescein release into
the surrounding medium within
60min. However, after lysis of the
lipid bilayer upon triton addition,
prompt release of fluorescein was
observed (red curve).
7.1.1 Synthesis and characterization of SLB@CMS
To study the mode of action of single colloidal mesoporous silica nanoparticles coated with an intact
supported lipid bilayer (SLB@CMS), the samples were prepared in a procedure displayed in Figure
7.1. Lipids were mixed in chloroform, desiccated and finally dispersed in a mixture of 60%vol water
and 40%vol ethanol (see Figure 7.1a) by the group of Prof. Joachim Rädler. The lipids were labeled
with BODIPY as a fluorescent dye for subsequent stability and tracking as well as co-localization
studies. In parallel, CMS nanoparticles were synthesized by Dr. Valentina Cauda following the
delayed co-condensation approach to achieve nanoparticles with an unfunctionalized core and an
amino-propyl functionalized outer surface [9]. The external aminopropyl surface has been selectively
functionalized with the dye ATTO633 (Figure 7.1b). Characterization measurements showed that
spherically shaped nanoparticles with an average size of 50-80 nm and a mesoporous structure with
pore sizes of about 3.7 nm were obtained. The particles were then employed for the synthesis of
SLB@CMS using a solvent-exchange method. In this method monomeric lipids (DOPC or POPC,
see Figure 7.1d) dissolved in ethanolic solution self-assemble into solid surface-supported bilayers or
liposomes as the water content of the solution is increased toward 100%vol [228]. By suspending the
CMS nanoparticles in the lipid solution, a supporting surface is offered for lipid bilayer formation
upon water addition to the solvent (up to 95%vol), thus allowing a direct and efficient coverage of the
silica surface (Figure 7.1c). The resulting SLB@CMS nanoparticles have a size of about 60-100 nm.
To probe the effective assembly and integrity of the supported lipid bilayer on single CMS nanopar-
ticles in vitro, dye release studies were performed by Dr. Valentina Cauda. For this studies the dye
fluorescein was loaded into the CMS nanoparticles and the particles were capped by a DOPC-SLB.
The particles were subsequently confined in a tube sealed by a dialysis membrane which is imperme-
able for the particles, but permeable for fluorescein. This tube was placed on a fluorescence cuvette
filled with water and the emission intensity of the solution in the cuvette was measured after exci-
tation with 512 nm light. In case of fluorescein-loaded, but uncoated CMS (without supported lipid
bilayer), a fast fluorescence increase in the cuvette was observed reaching a plateau after 10 min (see
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blue line with boxes in Figure 7.2). In contrast, fluorescein-loaded SLB@CMS nanoparticles (with
intact lipid bilayer) show no fluorescence increase within 1h. After disruption of the lipid bilayer
by the surfactant triton X-100, however, the fluorescein fluorescence increased up to the value of
the uncapped control sample within 60 min (see red line with triangles in Figure 7.2). The data
suggest that SLB@CMS nanoparticles are an intact and defect-free delivery system for fluorescein
showing no dye leakage from the particles in the observed time interval of 1 hour. However, the
release kinetics from the capped, but lysed CMS (100% within 60 min) is much slower than from
the uncapped CMS (100% released dye within 10 min). A probable explanation for this effect is the
higher diffusion resistance for the dye molecules due to the presence of lysed lipid fragments on the
CMS surface. Due to the positive results in vitro, the nanoparticle uptake and mode of action on a
single-cell level were examined by live-cell imaging.
7.1.2 Mode of cellular uptake of POPC-SLB@CMS
The first barrier nanoparticles encounter in cell culture is the plasma membrane of the cell. Besides
endocytosis, fusion of the particles bilayer with the cellular plasma membrane is another possible way
of nanoparticles internalization into cells, as reported for some enveloped viruses [229] and artificial
model cell systems [230]. To learn more about the mode of uptake of SLB@CMS nanoparticles, dual-
color SLB@CMS nanoparticles were prepared with BODIPY-labeled POPC lipids in the SLB and
ATTO633-labeled CMS nanoparticles. The particles have been incubated with HuH7 cells for up to
4 hours and the fluorescence of both the ATTO633-labeled nanoparticles and the BODIPY-labeled
SLB were recorded in two separated channels on a spinning disk confocal fluorescence microscope.
Under the measurement conditions, no crosstalk of the dyes was detected. The channels were merged
after acquisition. Co-localization of both BODIPY and ATTO633 fluorescence signals indicates
intact uptake via endocytosis. In case of fusion or hemi-fusion with the plasma membrane, we
expect a loss of BODIPY fluorescence on the particle location.
An overlay of the two channels is shown in Figure 7.3a. The fluorescence of BODIPY-labeled POPC
lipid and ATTO633-labeled nanoparticles are displayed in Figure 7.3b and c respectively. The results
clearly show co-localization of both components over the entire time span of the experiment, even
after the particles have been internalized by the cell which was verified by the particle’s localization
in the z-stack and their motion pattern with active transport along microtubules. In addition to
HuH7 cells, HeLa and 3T3 cells were examined with respect to their uptake route. However, all
three cell lines showed similar results. From the data, we can conclude that the particles have been
mainly internalized by endocytosis resulting in particles with intact bilayer as indicated by the two
colors.
7.1.3 Colchicine delivery from SLB@CMS nanoparticles
Despite the fact that the SLB-coated CMS nanoparticles are primarily taken up into the cells by
endocytosis and therefore end up trapped inside endosomes or lysosomes, we wanted to examine
whether the SLB@CMS nanoparticles still have the ability to deliver drugs to cells. Therefore we
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a b c
Figure 7.3: Co-localization of BODIPY-labeled lipids and ATTO633-labeled CMS of the
POPC-SLB@CMS after 117 min of incubation with HuH7 cells. HuH7 cells have been exposed
to POPC-SLB@CMS for 117 min. The lipids are labeled with BODIPY (green) and CMS is labeled with
ATTO633 (magenta). (a) Overlay of the green BODIPY channel (shown in b) and the magenta ATTO633
channel (shown in c). White spots indicate co-localization, corresponding to intact POPC-SLB@CMS
nanoparticles. The white circle and line show the nucleus and cell border respectively, as determined by a
transmitted light image. All the particles are within the cell border and show co-localization of lipid and
CMS fluorescence. The images are overlays of three z-planes. Scale: 10 µm.
loaded CMS nanoparticles with the anti-cancer drug colchicine. Once inside the cytosol, colchicine
forms stable complexes with tubulin heterodimers [231], the building blocks for microtubules and ef-
fectively inhibits and perturbs the assembly dynamics at the microtubule ends [232]. As microtubules
are essential for cell division, the ability of cells to proliferate is inhibited by colchicine [233]. After
colchicine-loading into unlabeled nanoparticles a POPC lipid bilayer was formed and free colchicine
was removed by centrifugation. HuH7 cells expressing GFP-labeled tubulin were incubated with the
POPC-SLB@CMS nanoparticles for 6 to 7 hours. The morphology of the GFP-labeled microtubules
was imaged on a spinning-disk confocal microscope (see Figure 7.4). As a result, untreated control
cells (Figure 7.4a) show an intact microtubule network. Incubation of cells with colchicine-loaded
nanoparticles, however, cause cell morphologies with disordered microtubuli, nuclei as well as cell
edges (Figure 7.4b). These findings indicate that colchicine-loaded POPC-SLB@CMS nanoparticles
are causing toxic effects on cellular microtubules. However, the mechanism of colchicine delivery
was not clear at that stage of the experiments.
To understand the mechanism of colchicine delivery in more detail and to trace individual colchicine-
loaded CMS nanoparticles, we incubated ATTO633-labeled nanoparticles with HuH7 cells containing
GFP-labeled microtubules. This allows an interpretation of the observed effects on a single-cell level.
Imaging was performed on a spinning disk confocal microscope using two detection channels for the
separation of fluorescence signals above and below 592 nm respectively. The two detection channels
were overlaid to obtain the images shown in Figure 7.5. A well-ordered and intact microtubule
network is observed for both untreated HuH7 cells (representative cells shown in Figure 7.5a in
green) and cells (in green) incubated with colchicine-loaded POPC-SLB@CMS nanoparticles (in
magenta) for 25 min (Figure 7.5b). However, after 2 hours of colchicine-loaded POPC-SLB@CMS
47
7 Lipid bilayer-coated CMS nanoparticles
cells with
POPC-SLB@CMS
colchicine-loadeduntreated cells
a b
Figure 7.4: Effect of non-labeled SLB@CMS loaded with colchicine on the microtubule mor-
phology of HuH7 cells. (a) Spinning disk confocal microscopy of untreated HuH7 cells shows intact GFP-
labeled microtubules (in green). (b) Cells incubated with colchicine-loaded, unlabeled POPC-SLB@CMS
for 8 hours show clear signs of colchicine toxicity. A lack of microtubule filaments together with disrupted
nuclear morphology and cell edges can be observed. Scale bar: 10µm.
incubation with the cells, the well-structured network has vanished and microtubule fragments and
a diffuse green fluorescence is detected. A cross-section through the cell volume (inset in Figure
7.5c) clearly shows internalized nanoparticles appearing in white due to the overlay of the green cell
interior and the magenta nanoparticles. In addition, several magenta spots can be detected on the
cell surface. 24 min later, the morphology of the same cell has changed dramatically as demonstrated
in Figure 7.5d. The cell shrunk and appears to be flat and dead. We attribute the observed effects
to the uptake of colchicine-loaded POPC-SLB@CMS nanoparticles into cells. Previous quenching
studies with nanoparticles (polyplexes, magnetic lipoplexes and PEGylated CMS nanoparticles)
showed, that after 20 min only a small fraction of the applied particles (16-20 % in case of polyplexes
and magnetic lipoplexes in HuH7 cells and 22 % of the PEGylated CMS in HeLa cells) have been
internalized [1, 2, 234]. This is an explanation, why after 25 min no colchicine-induced effects were
visible on the HuH7 cells. However, we know that the uptake of nanoparticles into cells increases
with time [235], leading to a considerable degree of internalization after 2 hours. Therefore, it is not
surprising that the toxic effect of colchicine was found to be pronounced at this timepoint. Therefore,
our model is the following: Colchicine-loaded POPC-SLB@CMS are taken up into the cell, followed
by a release of the colchicine of the nanoparticles, leading to microtubule depolymerization and cell
death. However, it is still not known how exactly the colchicine is released.
To study the release mechanism in more detail, we performed control experiments. First, we wanted
to verify that the internalized carrier POPC-SLB@CMS alone is not responsible for the loss of mi-
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Figure 7.5: Drug delivery by colchicine loaded POPC-SLB@CMS nanoparticles to HuH7 cells.
(a) Spinning disk confocal live-cell imaging of untreated HuH7 cells showing GFP-labeled microtubuli
(green). (b) HuH7 cells (green) exposed to colchicine-loaded POPC-SLB@CMS (CMS in magenta) for
25min. (c) After 120min of incubation, the microtubule network vanished resulting in a diffuse fluores-
cence. Inset: Side view of the same HuH7 cell with internalized nanoparticles depicted in white (overlay
of green and magenta colors) and nanoparticles on top of the cell in magenta. (d) After 144min the cell
morphology was disintegrated, indicating cell death. Scale bar: 10 µm.
crotubule structure. In this experiment, unloaded POPC-SLB@CMS nanoparticles were incubated
with HuH7 cells for 2 hours. Location of the particles within the cell volume was verified by a
z-stack combined with typical, intracellular motion. Figure 7.6a shows a representative HuH7 cell
with intact microtubule network (green) and internalized POPC-SLB@CMS nanoparticles (shown
in magenta). We conclude that the lipid-coated carrier taken up into the cell does not have an effect
on the microtubule network of the cell. The observed toxicity should therefore be attributed to
colchicine, the loaded drug. It is known that colchicine has a small permeability across cell mem-
branes [236], the question is, how much colchicine is subject to premature release. In a second set
of control measurements, we therefore studied how the colchicine is released from the carrier. Dr.
Valentina Cauda performed in vitro release experiments in a fluorescence cuvette for this purpose.
Colchicine was loaded into the CMS nanoparticles, a POPC lipid bilayer was built and the particles
were loaded into the tube sealed by a dialysis membrane. This tube was placed on a fluorescence
cuvette filled with water and the emission intensity of colchicine leaking out of the particles and
through the dialysis membrane into the solution was measured for 115 min. Indeed, a slight release
of colchicine was observed within the first 60-80 min reaching a plateau afterwards (see Figure 7.6b).
SLB disruption by ethanol lead to a significant increase in colchicine fluorescence in the cuvette. In
this control measurement, we wanted to investigate the effect of colchicine leached from the nanopar-
ticles into the cell culture medium before cellular uptake of the nanoparticles. Therefore, instead
of adding the colchicine-loaded POPC-SLB@CMS nanoparticles directly into the cell medium, we
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Figure 7.6: Effect of POPC-SLB@CMS and leaked colchicine on HuH7 cells. (a) HuH7 cells
(green) after 2 h of incubation with POPC-SLB@CMS without colchicine (magenta). (b) In vitro release of
colchicine from POPC-SLB@CMS, using the dialysis-capped tube fitting on the fluorescence cuvette. (c)
HuH7 cells exposed to released and dissolved colchicine from POPC-SLB@CMS that have been confined
into the dialysis-capped tube on the cell culture holder. After 6 h the microtubule network of the HuH7
cells was still intact. Scale bar: 10 µm.
pipetted the same amount of nanoparticles (used for the experiments shown in Figure 7.5) into the
cap used for the in vitro release experiment. The cap was closed with the dialysis membrane and
the membrane was brought in contact with the cell culture medium covering the HuH7 cells. In
this arrangement only released colchicine, but not the nanoparticles can diffuse through the dialysis
membrane and get in contact with the cells. Even after 6 hours of exposure to free colchicine dif-
fusing out of the drug-loaded POPC-SLB@CMS nanoparticles, the microtubule network remained
intact (see Figure 7.6c). This result suggests that the amount of colchicine leaking out of the SLB
is too low to induce microtubule depolymerization and cell death. Thus, cell death is caused by
colchicine delivery from POPC-SLB@CMS into the HuH7 cells.
In summary, we developed and tested a new drug delivery platform, CMS nanoparticles covered with
a supported lipid bilayer in vitro, and in living cells. The lipid bilayer proved to be a seal against pre-
mature release of fluorescent dyes and even a good barrier against the slightly membrane-permeable
drug colchicine. We showed, that colchicine delivery mediated by SLB@CMS nanoparticles is more
efficient than the same dose of drug in solution. We postulate, that this is due to delivery of a
small, concentrated dose inside the cell rather than a slow infiltration of colchicine from a diluted
extracellular pool. This enhancement effect, if substantiated in systemic delivery, would improve
cancer drug administration as lower drug doses could be applied to the patients.
Despite the fact that we successfully delivered colchicine to cancer cells, this system has the disad-
vantage that the mechanism of drug delivery was dependent on the ability of colchicine to permeate
through lipid bilayers. One idea to overcome this problem and to make the system applicable for
membrane-impermeable drugs as well, is to induce fusion of the particles on the plasma membrane
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Figure 7.7: Lipids examined as supported lipid bilayers on CMS nanoparticles. DOPE and
DOPC are neutral phospholipids. DOTAP and DDAB are cationic lipids.
or endosomes leading to delivery of the nanoparticle into the cytoplasm while retaining the lipid
bilayer on the membrane.
7.2 Variation in SLB composition and the influence on CMS
uptake
In Chapter 7.1, we studied the uptake of POPC-SLB@CMS nanoparticles and delivery of colchicine
into living HuH7 cells. The nanoparticles showed internalization into cells by endocytosis. To avoid
endo/lysosomal degradation, fusion of SLB@CMS nanoparticles with the plasma membrane of living
cells has the potential to deliver CMS to the cytoplasm, while retaining the SLB at the plasma
membrane. Experimental data on lipid vesicle fusion indicates that variation in lipid composition
plays an important role for fusogenicity [227]. Therefore, we studied the influence of different lipid-
compositions on the mode of cellular uptake and possibly find a composition featuring fusion.
To find SLB@CMS nanoparticles that are fusion-competent, CMS nanoparticles were equipped
with supported lipid bilayers of dioleoyl-phosphatidylethanolamine (DOPE), dioleoyl-sn-glycero-3-
phosphocholine (DOPC), dioleoyl-trimethylammonium propane (DOTAP), didodecyldimethylam-
monium bromide (DDAB) (see Figure 7.7) and mixtures thereof. In addition the positively-charged
surfactant cetyltrimethylammonium bromide (CTAB) has been mixed with the lipids in different
molar ratios. The dye-labeled lipid compositions have been provided by Dr. Hanna Engelke from
Prof. Joachim Rädler’s research group. For preparation of SLB@CMS nanoparticles, we used the
solvent exchange method as described in Chapter 7.1.1.
7.2.1 Characterization of SLB@CMS nanoparticle integrity
To study the fusogenic activity of different lipids as SLB, it is essential to prepare intact SLB-
sealed CMS nanoparticles. To examine the integrity, dual-color SLB@CMS nanoparticles have been
prepared. The dual-color nanoparticles carry the fluorescent dye ATTO633 bound to the external
aminopropyl surface of the CMS nanoparticles. The second label, BODIPY, is attached to the
applied lipids. Lipids were chosen according to their favorable role in fusion. In general, liposomal
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Figure 7.8: Integrity of SLB@CMS with different lipid compositions. SLB@CMS nanoparticles
with varying lipid composition have been prepared and imaged on coverglass by wide-field (b-e, g-i) and
spinning disk confocal microscopy (a and f). Co-localization of the nanoparticle and lipid bilayer fluores-
cence have been measured for SLBs composed of (a) DOPE ,(b) DOPE:CTAB 1:2, (c) DOPE:CTAB 1:1,
(d) DOPE:CTAB 2:1, (e) DOPE:CTAB:DOPC 1:1:1, (f) DOPE:DOTAP 1:1, (g) DOPE:DDAB 1:2, (h)
DOPE:DDAB 1:1 and (i) DOPE:DDAB 2:1 (molar ratios). Scale bar: 5 µm.
formulations oftentimes contain two lipid species, for example a cationic amphiphile combined with
a neutral phospholipid, such as DOPE [237]. DOPE is known as a fusion-promoting lipid [238] with
high destabilization properties. It was shown to promote fusion of lipid:DNA complexes with cellular
membranes [237]. Lipid vesicle formulations containing DOPE were shown to be more fusogenic than
the ones containing the neutral phospholipid DOPC [239]. However, as a widely-used helper lipid
that fosters lipid bilayer formation, DOPC has been included in one of the formulations in this
work. The cationic lipid DOTAP is known to be non-fusogenic [240]. However, in combination with
DOPE (in ratios of DOPE/DOTAP, 1:9, 1:2.3, 1:1, 2.3:1, 9:1 molar proportion) it was shown to fuse
with model membranes consisting of DOPS/DOPE/DOPC in a molar proportion of 1:1.7:4 [230].
Another cationic lipid, used in our study, is DDAB. DDAB liposomes were shown to be unstable at
physiological pH and temperature, but the mixture of DDAB with DOPE (2.5:1) increased stability
[241].
To assess the integrity of SLB@CMS nanoparticles and for further studies on living cells, co-
localization of lipid bilayer (SLB) and nanoparticles was examined directly after sample preparation
and before addition to the cells. Therefore, dual-color SLB-coated CMS have been sedimented on
glass coverslips. The fluorescence of the nanoparticles was recorded in two separate channels for the
detection of ATTO633-labeled CMS and BODIPY-labeled SLB, respectively. To remove out of focus
fluorescence, a rolling ball background filter of 8 pix has been applied. Co-localization of BODIPY-
labeled SLB and ATTO633-labeled CMS indicates intact particles. Representative co-localization
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images are displayed in Figure 7.8. Successful synthesis is observed in case of DOPE-SLB@CMS
nanoparticles. The nanoparticles show good co-localization of the BODIPY-labeled DOPE-SLB
(depicted in green in Figure 7.8a) and ATTO633-labeled CMS (depicted in magenta in Figure 7.8a).
Co-localization is indicated by white color due to overlay of green and magenta colors. In further
samples, the addition of CTAB to the DOPE-bilayer in ratios of DOPE:CTAB 1:2 and 1:1 leads to
large amounts of CMS without lipid bilayer (magenta only spots in Figure 7.8b and c). The samples
are therefore not applicable for our cell experiments where nanoparticles without supported lipid
bilayer are counted as fusogenic. This would lead to false-positive results. Reducing the amount
of CTAB, such as in the sample DOPE:CTAB in the ratio of 2:1, leads to dual-color nanoparticles
applicable for fusion experiments (see Figure 7.8d). Further addition of DOPC in a molar ratio of
DOPE:CTAB:DOPC 1:1:1, as shown in Figure 7.8e, gives co-localizing dual-color CMS nanoparticles
and will be used for the cell experiments. Reduced co-localization is found in case of DOPE:DOTAP
in the molar ratio 1:1. Most of the nanoparticles were found dual-color, however, the sample prepa-
ration was inhomogeneous showing both green only and magenta only signals (see Figure 7.8f). This
renders DOPE:DOTAP unsuited for cell experiments. DOPE:DDAB 1:2 preparation showed a ma-
jority of CMS nanoparticles without lipid bilayer. Further reduction of the DDAB content lead to
better lipid bilayer formation, however, there were still numerous nanoparticles without lipid bilayer
(see Figure 7.8g-i). Therefore, the DOPE:DDAB samples are not applicable for our co-localization
studies.
To sum up, the experiment gave insight in the intactness of SLB formation on CMS depending on
the lipids applied. Intact dual-color nanoparticles are a prerequisite for the experiments on a single-
cell level. However, in this control experiment, we can not draw conclusions about fusogenicity of
the lipid compositions. Pure DOPE-bilayers, SLB made from DOPE:CTAB in the ratio of 2:1 and
SLB made from DOPE:CTAB:DOPC in the ratio of 1:1:1 turned out to be useful for experiments
on nanoparticle uptake modes in living cells.
7.2.2 Mode of uptake for various SLB@CMS nanoparticles into living cells
After identification of lipid bilayer compositions that yield intact dual-color SLB@CMS nanoparticles
(DOPE, DOPE:CTAB 2:1 and DOPE:CTAB:DOPC 1:1:1), the role of fusion for internalization
of these compositions was determined. For this, HuH7 cells were incubated with the dual-color
SLB@CMS nanoparticles for multiple hours to ensure a high degree of intracellular location. Fluo-
rescence microscopy of the cells has been performed in two channels to detect BODIPY-labeled lipids
and ATTO633-labeled CMS, respectively. To remove out of focus fluorescence from different cellular
planes, a rolling ball background filter of 8 pix has been applied [217]. Internalized nanoparticles are
detected by their typical motion pattern showing active transport. Co-localization analysis indicates
that internalized particles, showing both BODIPY and ATTO633 fluorescence, have been taken up
via endocytosis, whereas nanoparticles with intracellular CMS-ATTO633 fluorescence without co-
localizing lipid-headgroup BODIPY fluorescence fused with the target cell membrane.
DOPE-SLB@CMS nanoparticles have been incubated with HuH7 cells for 3 h. Image acquisition
occurred on a spinning disk confocal microscope in three successive z-planes through the cell in-
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Figure 7.9: Co-localization of cell associated nanoparticles consisting of BODIPY-labeled
lipids and ATTO633-labeled CMS. HuH7 cells have been exposed to SLB@CMS for multiple hours.
CMS is labeled with ATTO633 (magenta) and the lipids are labeled with BODIPY (green). The lipid
bilayers consisted of (a-c) DOPE, (d-f) DOPE:CTAB 2:1 and (g-i) DOPE:CTAB:DOPC 1:1:1. For the cor-
responding lipid compositions, overlays (shown in a, d, g) of the magenta ATTO633 channel (shown in b, e,
h) and the green BODIPY channel (shown in c, f, i) have been performed. White spots in the overlay images
indicate co-localization, corresponding to intact SLB@CMS nanoparticles. All the cell-associated particles
show co-localization of lipid and CMS fluorescence. The images are filtered by a rolling ball background
filter of 8 pix. Scale bar: 5 µm.
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terior. The z-planes were overlaid as well as the two channels. Co-localization of CMS-ATTO633
nanoparticles (depicted in magenta, Figure 7.9b) with the BODIPY-labeled DOPE-SLB (depicted
in green, Figure 7.9c) is displayed in Figure 7.9a. As the internalized particles still co-localize with
their DOPE-SLB (white color in Figure 7.9a), there was no indication, that -under our measure-
ment conditions- fusion on the plasma membrane of the cells is the predominant uptake route.
DOPE:CTAB 2:1 as SLB on CMS nanoparticles have been incubated with the cells for 6.75 h and
imaging occurred on a fluorescence wide-field microscope in two channels. Complete co-localization
(see Figure 7.9d) of all CMS-ATTO633 nanoparticles (depicted in magenta in Figure 7.9e) with
BODIPY-labeled SLBs consisting of DOPE:CTAB (depicted in green in Figure 7.9f) is observed.
DOPE:CTAB:DOPC in a composition of 1:1:1 as SLB on CMS nanoparticles has been incubated
with HuH7 cells for 8.5 h. Imaging occurred by wide-field fluorescence microscopy. The results are
depicted in Figure 7.9g-i. Co-localization analysis showed that all internalized nanoparticles were
dual-color. One possible explanation is that the lipid bilayer is stabilized by its CMS support leading
to reduced interactions with the cellular membranes. Taken together, the data suggest that none
of the tested SLB-compositions induced fusion of the SLB@CMS nanoparticles with the plasma
membrane.
In summary, out of nine tested lipid compositions, only three formed intact supported lipid bilayers
on the CMS nanoparticles. The compositions yielding functional dual-color nanoparticles were
DOPE, DOPE:CTAB 2:1 and DOPE:CTAB:DOPC 1:1:1. After long incubation times of multiple
hours, the CMS nanoparticles have been internalized together with their SLB. This means that fusion
on the plasma membrane of the cells is not the predominant uptake route for the tested compositions.
Ideas for improvements to finally achieve fusion on the plasma membrane can be found in biological
systems where fusion is highly regulated and mediated by specialized proteins. Prominent examples
of fusion proteins are glycoproteins of enveloped viruses such as the hemagglutinin fusion protein
of influenza virus [242]. In addition, SNARE proteins are crucial for the intracellular membrane
fusion processes in eukaryotes [243]. The application of fusion proteins in a lipid bilayer might help
to facilitate fusion on the plasma membrane.
7.3 Summary
In this chapter, we presented an efficient and reproducible method, based on solvent exchange, to
encapsulate individual core-shell CMS nanoparticles of 50 nm diameter with an intact lipid bilayer.
The novel SLB@CMS nanoparticles feature a high capacity for the incorporation of drugs into the
mesopores. In vitro experiments show the complete sealing of the CMS nanoparticle by the lipid
bilayer and the absence of premature release of guest molecules such as dyes and prove the stability
of the SLB acting as a capping system. The in vitro displacement of the lipid bilayer by triton leads
to the opening of the mesopores. Uptake experiments showed that SLB@CMS nanoparticles were
taken up intactly by endocytosis. As a proof of principle, we showed the delivery of the microtubule
depolymerizing drug colchicine into HuH7 liver cancer cells. This experiment clearly exposes the
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important role of the SLB, mostly preventing the release of the drug under undesired conditions
and allowing delivery into the cell by uptake of the nanoparticles. The microtubule network of
the cells is destroyed within 2 h of incubation with the colchicine-SLB@CMS nanoparticles, thus
showing an enhanced effect compared to the same dose of colchicine in solution. We believe that
the enhancement is due to the fact that colchicine delivery mediated by SLB@CMS nanoparticles
results in small concentrated doses rather than slow infiltration of colchicine from a rather diluted
extracellular pool. However, the proposed system has the disadvantage that it is not applicable
for membrane-impermeable drugs. One idea to overcome this problem is to induce fusion of the
particles on the plasma membrane leading to delivery of the nanoparticle into the cytoplasm while
retaining the lipid bilayer on the cellular membrane. The cell entry mechanism would open the pores,
enabling intracellular release of the cargo. Different lipids have been examined as supported lipid
bilayer on CMS, however, most of them did not form intact dual-color SLB@CMS nanoparticles. In-
cubation of DOPE, DOPE:CTAB in a molar ratio of 2:1 and DOPE:CTAB:DOPC 1:1:1 SLB@CMS
nanoparticles with HuH7 cells for multiple hours revealed that the nanoparticles show endocytosis
as their major mode of uptake. Further screening of different lipid compositions might help to find a
fusion-competent lipid bilayer composition, however further modification of the nanoparticles with
fusion proteins or peptides is more promising.
In summary, SLB@CMS nanoparticles is a good system for pore sealing after drug loading, one
major drawback of the system is, that it is not useful for “controlled drug release”. Therefore, in a
next step a system with the ability for controlled release was developed.
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In the previous chapter, we reported on SLB-coated CMS that are taken up into cells by endocy-
tosis and release colchicine, however, not in a controlled fashion. To achieve controlled drug release
into the cytosol, various stimuli can be applied (for details see Chapter 3.3). One such stimulus
is light irradiation. To perform light-triggered drug release and to overcome the endosomal mem-
brane as a barrier to cytosolic drug delivery, we used photochemical internalization (PCI). PCI is
based on light activation of a photoactive compound (photosensitizer). One such photosensitizer
is the amphiphilic porphyrin derivative disulfonated meso-tetraphenylporphine (TPPS2a). Due to
its chemical composition (see Figure 8.1), it inserts into the plasma membrane -while incubated
with the cells- and specifically locates in the membrane of endocytic vesicles [81, 244, 245]. Upon
exposure to light of 405 nm, TPPS2a is excited to its singlet state, followed by intersystem crossing
to its triplet state. This excited state is then quenched by triplet oxygen producing highly reactive
oxygen species (ROS) [246], such as singlet oxygen. Singlet oxygen in turn is able to oxidize amino
acids, unsaturated fatty acids, cholesterol and leads to the collapse of the endosomal membrane
followed by release of the endosomal content into the cytosol [80]. It is important to note, how-
ever, that the range of action of singlet oxygen remains locally confined (10-20 nm) due to its very
short lifetime of 10-40 ns inside cells [247]. For this reason, singlet oxygen mainly reacts with the
endosomal membrane and the damage to the endosomal cargo is expected to be low.
The CMS nanoparticles to be delivered by PCI are designed for redox-driven intracellular disulfide-
cleavage, releasing the cargo upon contact with the reducing milieu of the cytoplasm. To achieve
this the cargo molecules are bound via a disulfide linker to the inner volume of CMS nanoparticles.
This procedure has the advantage that the cargo is protected inside the porous host material while
no synthetically demanding valve is needed to prevent premature release of the cargo. The concept
of disulfide-bound agents inside the pore system of mesoporous silica has been initially studied
by Mortera et al. [124]. The authors used the membrane-impermeable amino acid cystein (Cys)
as a cargo. Cystein delivery into cells promotes the synthesis of glutathion (GSH), which plays
a central role in cell biology and is depleted in a number of diseases including cancer as well as
neurodegenerative and cardiovascular diseases [248]. For the study of Mortera et al., Cys was
released from MSN based on disulfide bridge cleavage [124]. However, the authors did not report on
the cellular uptake mechanism and the specific locus as well as the time point of reduction inside the
cells. In the following, we elucidate the role of endosomal escape for disulfide-based drug delivery
from CMS nanoparticles by real-time live-cell imaging of the photochemical release process. The
results of this study are described in this chapter and have been published in Nano Letters (see
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Figure 8.1: TPPS2a. Chemical structure of disulfonated meso-tetraphenylporphine with the sulfonate
groups on adjacent phenyl rings (TPPS2a).
reference [13]).
First, a short description of the particle synthesis and the applied samples will be given. In a second
part, the cargo release of disulfide-bridged CysATTO633 from CMS upon addition of a reducing
agent will be monitored by single-particle fluorescence microscopy in vitro. Afterwards, live-cell
imaging of HuH7 cells incubated with the nanoparticles for up to two days will be presented. In
a last step, photochemically induced endosomal release of CMS is followed by live-cell imaging.
Imaging of the release process in great detail enables mechanistic insights and further improvements
on the drug delivery systems.
8.1 Synthesis of CMS for disulfide-based drug delivery
CMS nanoparticles for disulfide-based drug delivery have been synthesized by Dr. Axel Schlossbauer
from the group of Prof. Thomas Bein (LMU Munich). The particles were prepared according to
the sequential co-condensation method with a mercaptopropyl-functionalized core, surrounded by
pure silica and an aminopropyl-functionalized shell. After template extraction, CMS nanoparti-
cles have a diameter of 80 nm and a pore size of 3.8 nm. In case of the CMS nanoparticles for
disulfide-based drug delivery, the aminopropyl-functionalized shell was labeled with ATTO488 and
the mercaptopropyl-functionalized core was activated with 2-2’-dithiopyridine (DTP), followed by
reaction with ATTO633-labeled cystein. This resulted in disulfide-bridged, ATTO633-labeled cys-
teine attached to the inner pore walls of the particle core (see Figure 8.2a). The sample will be
referred to as CMS-CysATTO633core-ATTO488shell. The synthesis of this sample has been mon-
itored by Raman spectroscopy (for details see [13, 249]). In addition, three other samples have
been prepared. The sample CMS-CysATTO633core-NH2shell contains an unlabeled shell (see Figure
8.2b). The samples CMS-ATTO633core-ATTO488shell and CMS-ATTO633core-NH2shell are control
samples without disulfide-linker. Both samples contain ATTO633-labeled cores (see Figure 8.2c and
d), but ATTO633 is not bound via disulfide bridges and is therefore uncleavable in reducing milieu.
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Figure 8.2: CMS samples for disulfide-based drug delivery.
8.2 Single-particle characterization in vitro
To examine whether the disulfide bridges inside the nanoparticle core are cleavable by reductive
milieu, first experiments have been performed in vitro with CMS nanoparticles on glass. This first
proof of principle measurements are essential to be able to interpret the more complicated cell culture
experiments later on. The aim was to follow the release of dye-labeled cysteine at a single-particle
level by fluorescence microscopy on-line. Therefore, CMS nanoparticles were dispersed in water,
sedimented on glass coverslips and incubated with the reducing agent 10 mM GSH. Before (t < 0 min)
and after (t > 0 min) addition of GSH, movies of the nanoparticles were recorded. From the movies,
the mean fluorescence intensities of ATTO633-labeled particles and the background were extracted.
The obtained intensities were normalized and plotted versus time (Figure 8.3). In Figure 8.3a, the
relative CysATTO633 fluorescence intensities of CMS-CysATTO633core-ATTO488shell nanoparticles
(black) and background (gray) are displayed. After GSH addition, the CysATTO633 fluorescence
of the background (gray curve) increases up to a factor of 2.3 reaching a plateau after 8 min. The
increase of CysATTO633 background fluorescence intensity indicates successful release of the dye
from the CMS nanoparticles and distribution of the cargo on the cover glass.
Surprisingly, the CMS-CysATTO633core-ATTO488shell nanoparticles themselves (shown in Figure
8.3a, black curves) also showed an increase in CysATTO633 fluorescence intensity. This increase
by a factor of 2 or more occurred within two minutes, on a faster time scale than the increase in
background fluorescence, and was unexpected. Instead, we expected a decrease in the particle’s
CysATTO633 intensity after reductive dye release. However, the increase of nanoparticle-associated
CysATTO633 intensity is easily explained by a dequenching effect of the pore-bound CysATTO633.
The tight packing of the dye molecules inside the pores promotes a self-quenching of CysATTO633
similar to tightly packed octadecyl rhodamine B or calcein in liposomes [250]. The release of dye
lowers the dye concentration within the pores below the limit for self-quenching and the residual
dye molecules start fluorescing. The strong fluorescence of the nanoparticles also indicates that the
disulfide-bound CysATTO633 is not completely released upon addition of GSH. The self-quenching
effect of tightly packed ATTO633 in a constrained environment such as mesoporous silica has not
been reported before. In our experiments, this self-quenching effect of CysATTO633 permits a
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Figure 8.3: CysATTO633 release measured in vitro on a single-particle level. The mean fluo-
rescence intensity of four single particles on glass (black curves) and background (gray curve) was ex-
tracted from a movie, normalized, and plotted versus time. The fluorescence intensity of ATTO633 was
plotted for (a) redox-cleavable CMS-CysATTO633core-ATTO488shell and (b) non-cleavable control CMS-
ATTO633core-ATTO488shell nanoparticles in water. At timepoint t=0min 10mM GSH was added to the
samples. The movies were recorded at 642 nm illumination with an exposure time of 200ms and a frame
rate of 3.4 s−1.
well-detectable readout for dye release with excellent signal-to-noise ratio.
As a control, CMS-ATTO633core-ATTO488shell nanoparticles without cleavable disulfide linker were
examined under similar conditions (Figure 8.3b). The fluorescence intensities of both the background
and the particles remained constant and a dequenching effect was not observed after addition of
10 mM GSH (at t = 0 min). This result confirms that only dyes bound via a disulfide linker are
released by GSH and that the release is associated with a strong increase of nanoparticle fluorescence
intensity.
To summarize, we showed that release of disulfide-bound CysATTO633 from CMS nanoparticles in
10 mM GSH can successfully be observed at a single-particle level. The release was accompanied by
a dequenching of the ATTO633 fluorescence and this effect permits a sensitive readout for successful
dye release. The results of the experiment enabled us to further apply the CMS nanoparticles on
living cells.
8.3 Long-term live-cell imaging of HuH7 cells incubated with
CMS nanoparticles
To investigate whether the reductive milieu inside living cells is able to induce dye release from
CMS nanoparticles, as monitored on glass, we examined living cells exposed to dual-color CMS-
CysATTO633core-ATTO488shell nanoparticles for up to 2 days. After this long time interval, we
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a b c
e fd
Figure 8.4: Spinning disk confocal
microscopy of living HuH7 cells
after long-term exposure to CMS-
CysATTO633core-ATTO488shell
nanoparticles. z-projections are
shown consisting of the overlay of three
planes inside an HuH7 cell exposed to
CMS-CysATTO633core-ATTO488shell
nanoparticles for 25 h (a-c) and 49 h
(d-f). The cell nucleus is indicated by
a white circle and the outer white line
represents the cell border. Fluorescence
of the particles’ core (magenta a and
d) and shell (green b and e) is highly
co-localized as indicated by the white
signal in the merged image (white c
and f), which was superimposed on
the transmitted light image of the cell.
Scale bar: 10 µm.
expect the particles to be internalized to a high extent. In case of successful intracellular reductive
CysATTO633 release, we expect to observe a reduction in co-localization between the two dyes.
To measure this, after 24 and 48 h of exposure, confocal z-stacks of HuH7 cells were acquired by
spinning disk confocal microscopy and the co-localization of CysATTO633core and ATTO488shell
was evaluated. Successful cell entry and intracellular localization of the CMS nanoparticles was
detected by their characteristic intracellular motion such as transport by motor proteins [1, 2, 29]
and the location within the z-stack.
Transmission light images of the cells showed no morphological signs of toxicity within our observa-
tion time. After 49 h, core-bound CysATTO633 and shell-bound ATTO488 signals of the intracellu-
lar particles were still co-localized. Additionally, fluorescence of free CysATTO633 in the cytoplasm
was not detected. This indicates that within 49 h the disulfide-bound dye was not released. Two
representative cells, after 25 h (Figure 8.4a-c) and 49 h (Figure 8.4d-f) of incubation, are displayed.
Fluorescence of the particle’s CysATTO633-core (magenta a and d) and shell (green b and e)
was co-localized as indicated by the white signal in the merged image (white c and f), which was
superimposed on the transmission light image of the cell.
Our results indicate that CMS-CysATTO633core-ATTO488shell nanoparticles are taken up into
HuH7 cells without detectable signs of toxicity. Reductive release of ATTO633-labeled cysteine
from internalized particles was not detected within 49 h of incubation.
From the data obtained on uptake into living cells, including our own study presented here, it has
been shown that cells internalize CMS nanoparticles into endocytic vesicles [13, 161, 251]. Entrapped
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Figure 8.5: Influence of a TPPS2a
solution on redox-cleavable CMS-
CysATTO633core-NH2shell. Redox-
cleavable CMS-CysATTO633core-NH2shell
nanoparticles were incubated in a TPPS2a
solution on glass coverslips on the microscope.
TPPS2a was activated by a 405 nm laser. A
movie was recorded at 642 nm illumination
with an exposure time of 200ms and a frame
rate of 3.4 s−1. The CysATTO633 intensity
of single particles on glass (black curves) and
background (gray curve) was extracted from
the movie, normalized and plotted versus time.
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in endocytic vesicles, CMS nanoparticles are not accessible to the reductive milieu of the cytosol.
Surprisingly, Mortera et al. showed cytosolic fluorescence of reductively released cysteine [124].
However, they did not show the release process itself. In our mechanistic study, we could not detect
reductive release of ATTO633-labeled cysteine.
8.4 Photochemically-induced endosomal release
To overcome the endosomal membrane barrier separating CMS nanoparticles from the cytosol and
to gain mechanistic insight into the release at a single-cell level in real-time, photoinduced endosomal
release is a promising strategy. In this method, the photosensitizer TPPS2a is incubated with the
cells and incorporates into membranes via the endocytic pathway. By 405 nm laser light, TPPS2a
is excited to its singlet state, followed by intersystem crossing to its triplet state. This excited state
is then quenched by triplet oxygen producing singlet oxygen. Singlet oxygen is highly reactive and
leads to a collapse of the endosomal membrane followed by release of the endosomal content into
the cytosol.
To ensure that 405 nm light-activated TPPS2a in solution has no influence on the fluorescence inten-
sity of CMS-CysATTO633core-NH2shell nanoparticles, control measurements have been performed
in vitro on glass. For this, redox-cleavable CMS-CysATTO633core-NH2shell nanoparticles in TPPS2a
solution have been sedimented on glass coverslips on the microscope. After activation of TPPS2a by
405 nm laser light for 1 min, a movie was recorded under 642 nm illumination. The CysATTO633 flu-
orescence intensities of single particles and background have been extracted, normalized and plotted
versus time (see Figure 8.5). The fluorescence intensities of both the background (Figure 8.5 gray
curve) and the particles (black curves) remain constant. This indicates that activated TPPS2a in
solution has no influence on the fluorescence intensity of CMS-CysATTO633core-NH2shell particles,
which is a prerequisite for further experiments in living cells.
To evaluate photochemically induced endosomal escape of CMS nanoparticles in living cells, a
marker for endosomal opening was needed. For this purpose, we incubated the cells with the
fluid phase marker Alexa Fluor 488 dextran (AFD). AFD is internalized by fluid-phase endocytosis
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Figure 8.6: Photoinduced endosomal release of CMS-CysATTO633core-NH2shell and fluid
phase marker AFD inside living HuH7 cells monitored by wide-field fluorescence microscopy.
The cells were exposed to the nanoparticles overnight. (a) Intensity plot of three exemplary tracked endo-
somes (highlighted by small circles in b and c) over time. The fluorescence intensity of CysATTO633 (upper
three curves) showed a sudden increase concomitant to the decrease in AFD fluorescence intensity (corre-
sponding lower three curves) due to endosomal rupture and AFD dye release. (b) Fluorescence microscopy
image overlays of the CysATTO633 (magenta) and fluid phase marker AFD (green) signal at activation of
the photosensitizer and (c) 4min later. The cell nucleus is indicated with the large white circle. Scale bar:
10 µm.
and is used as a label for endosomes [45]. Along with AFD, we incubated the cells with CMS-
CysATTO633core-NH2shell nanoparticles and the photosensitizer. After 18-24 h of incubation, the
cells were examined by wide-field fluorescence microscopy.
As a result, we found all CMS nanoparticles that exhibit typical intracellular motion to be co-
localized with AFD. This indicates successful internalization of the CMS nanoparticles into en-
dosomes. The AFD fluorescence intensity of the endosomes varied depending on the amount of
internalized AFD. Excitation of the photosensitizer was achieved by illumination of the sample with
405 nm laser for 1 min. This resulted in deceleration of endosomal motion until arrest, as reported
previously [30]. Depending on the amount of photosensitizer incorporated in the endosomal mem-
brane, the endosomes were ruptured within 1-4 min after 405 nm illumination. Endosomal rupture
lead to a spontaneous release of AFD into the cytoplasm as indicated by a sudden drop in endosomal
AFD fluorescence.
Concomitant with endosomal rupture and AFD release, the fluorescence intensity of the CMS-
CysATTO633core-NH2shell nanoparticles increased due to the dequenching effect, as described above
and presented in Figure 8.3a. Directly after photosensitizer activation the endosomes still show
predominantly AFD fluorescence (see Figure 8.6b depicted in green). Strikingly, only 4 min later
the same endosomes show only CysATTO633 fluorescence (Figure 8.6c depicted in magenta). Please
note that the diffuse magenta fluorescence within the nucleus area (big, white circle) is due to out
of focus particle fluorescence. With a size of 10 kDa, AFD can diffuse almost freely after endosomal
release, and is dispersed within the cytosol [252]. In contrast, due to their large size and impaired
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Figure 8.7: Photoinduced endosomal release of CMS-ATTO633core-NH2shell and fluid phase
marker AFD inside living HuH7 cells monitored by wide-field fluorescence microscopy. (a)
Intensity plot of three exemplary tracked endosomes (highlighted by small circles in b and c) over time.
The fluorescence intensity of ATTO633 (upper three curves) showed no or only slight increase concomitant
to the decrease in AFD fluorescence intensity (corresponding lower three curves) due to endosomal rupture
and AFD dye release. (b) Fluorescence microscopy image overlays of the ATTO633 (magenta) and fluid
phase marker AFD (green) signal at activation of the photosensitizer and (c) 4min later. The cell nucleus
is indicated with the large white circle. Scale bar: 10 µm.
motion in the crowded cell interior, the nanoparticles remain at their location.
As a control measurement, noncleavable CMS-ATTO633core-NH2shell nanoparticles without cysteine
linker were incubated with AFD and the photosensitizer for 12-24 hours. The internalized nanopar-
ticles showed co-localization with AFD until endosomal rupture. At endosomal rupture, the relative
fluorescence intensity of AFD showed a sudden drop, whereas the ATTO633 fluorescence remained
largely constant with a slight intensity increase by a factor of 1.25 (Figure 8.7a). This increase
might be due to a small amount of unreacted dye inside the mesopores, which is released from the
endosome after disruption of the endosomal membrane. The disruption of the endosomal mem-
brane and release of AFD occurred within 4 min, and the CMS-ATTO633core-NH2shell nanoparticle
fluorescence remained at the former endosomal regions (Figure 8.7c).
8.5 Summary
In this chapter, we presented mechanistic insights into disulfide-based drug delivery from CMS
nanoparticles. After particle synthesis, in vitro single-particle measurements of the nanoparticles on
cover glass showed that disulfide-bound CysATTO633 is released from CMS nanoparticles in 10 mM
GSH. Evaluation of the particle’s fluorescence intensity revealed that the dye release is accompanied
by a dequenching of the ATTO633 fluorescence. We therefore show, for the first time, that linkage
of ATTO633 at high concentration in the pores of silica nanoparticles results in quenching of the
ATTO633 fluorescence. This unexpected effect permits a sensitive readout for successful dye release.
Although the particles were shown to be functional and to release their cargo upon addition of a
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reducing agent, disulfide-based CysATTO633 release into HuH7 cells was not observed even after up
to 49 h incubation of CMS-CysATTO633core-ATTO488shell nanoparticles with the cells. Inefficient
endosomal escape of the nanoparticles is a bottleneck for molecular delivery into the cytoplasm.
To overcome the endosomal barrier, we used the photosensitizer TPPS2a. Upon activation of
the photosensitizer, CMS-CysATTO633core nanoparticles successfully released disulfide-bound Cys-
ATTO633 into the cytoplasm, however the resolution of our measurement setup does not allow
conclusions on the locus of reductive cleavage (endosome or cytoplasm). Our measurements confirm
that endosomal escape is the main bottleneck for disulfide-based drug delivery. In case of noncleav-
able CMS-ATTO633core nanoparticles without cysteine linker, release of ATTO633 was not observed
after endosomal rupture.
The proposed drug delivery system allows us to control the time of the endosomal rupture by use
of the 405 nm laser. However, TPPS2a shows a high toxicity to the cells, as highly reactive oxygen
species are produced where the photosensitizer is present. For further studies, we want to achieve
spatial control on the endosomal escape by covalently particle-bound photosensitizer. Using this
particle, we plan to limit singlet oxygen production and endosomal rupture only to the endosomes
containing photosensitizer-equipped nanoparticles (see Chapter 9).
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9 Cascaded photoinduced drug delivery from
mutifunctional PpIX-mesoporous silica
In the previous chapter, we reported on an approach using reductive cleavage of disulfide-bridged
compounds bound to the pore walls of mesoporous silica nanoparticles. We showed that endosomal
escape represents a bottleneck for this approach. Photochemical internalization (PCI) of a pho-
tosensitizer (PS) that induces endosomal escape by creating singlet oxygen has been proven to be
powerful to overcome this barrier (see Chapter 8). The PS, the porphyrin derivative TPPS2a, is
incubated with the cells. It inserts into the plasma membrane and, after endocytosis, locates in the
membrane of all endocytic vesicles. Therefore, all PS containing vesicles are subject to photoactiva-
tion upon irradiation and the spatial control on endosomal escape and the induced phototoxicity is
limited. To obtain spatial control on the photoactivity, association of the PS with the nanoparticles
is desirable.
In current literature, different groups have applied PS associated with mesoporous silica for other
purposes than PCI, such as photodynamic therapy or two-photon imaging [166, 253–255]. In addi-
tion, there are initial approaches to combine PS with mesoporous silica as drug carrier. However,
in these studies, the PS is not or not completely bound to the particles [256, 257]. This can lead to
uncontrolled leaching of the compounds and highly toxic effects on the cells [30]. To achieve a more
precise, “surgical” function of PS-equipped nanodevices and to minimize their toxicity on cells, it is
desirable to bind the PS directly to the surface of the mesoporous particles.
Therefore, we report how multifunctional core-shell colloidal mesoporous silica nanoparticles com-
bined with covalently surface-linked protoporphyrin IX (PpIX) as an on-board photosensitizer show
localized photoactivity along with controlled drug release. PpIX is a photosensitizer naturally oc-
curring in many cell types. The iron(II) complex of PpIX, called heme, is needed for binding to
different proteins to form hemoproteins such as hemoglobin [258]. For photochemical internaliza-
tion, PpIX in solution is not useful due to its low water solubility (around 1 µg/mL) [259]. The
low solubility can be overcome by delivery of PpIX into cells by a nanoparticle drug carrier. Once
inside the cell, PpIX can be effectively excited in its Soret band at around 410 nm. This excitation
initiates a cascade in which energy is transferred to molecular oxygen that oxidizes amino acids,
unsaturated fatty acids, cholesterol and various cellular compartments enabling endosomal escape
[80].
In this chapter, the synthesis of the CMS with covalently surface-linked PpIX and the applied
particle designs will be presented briefly. Afterwards live-cell imaging studies of CMS-PpIX for
disulfide-based drug delivery similar to the studies presented in Chapter 8 will be shown. To
improve the readout signal for successful drug delivery, we exchanged disulfide-based drug loading
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a
b
Figure 9.1: PpIX attachment to CMS nanoparticles. Attachment of amino-terminated PpIX (PpIX-
NH2) (a) to the PEGylated surface of CMS, leading to the sample CMS-PpIXshell (b).
towards adsorption of “model drugs”. To seal the pores after drug loading, the particles were further
equipped with a SLB. The activity of these SLB-coated CMS-PpIX nanodevices for photochemical
release was examined with regard to the release efficiency by wide-field microscopy on a single cell
level. In addition, successful drug release of “model drugs” of varying size was shown by spinning
disk confocal microscopy. The results give insight into the characteristics of this newly developed
drug delivery system. The project was performed in collaboration with Dr. Axel Schlossbauer, Dr.
Valentina Cauda and Alexandra Schmidt from the group of Prof. Thomas Bein; Dr. Hanna Engelke
from the group of Prof. Joachim Rädler and with Dr. Kourosh Zolghadr and Dr. Ulrich Rothbauer
from the group of Prof. Heinrich Leonhardt (all LMU Munich). Main parts of this chapter are
derived from a manuscript submitted for publication [14].
9.1 Synthesis of CMS-NH2core-PpIXshell
CMS nanoparticles with covalently surface-linked PpIX have been developed by Dr. Axel Schloss-
bauer and have been synthesized for our experiments by him, Dr. Valentina Cauda and Alexandra
Schmidt from the group of Prof. Thomas Bein (LMU Munich).
In brief, the recently developed sequential co-condensation process [9, 260] was used to generate core-
shell bifunctionalized colloidal mesoporous silica, exhibiting aminopropyl-groups on the inner pore
walls and 3-mercaptopropyl on the particles’ outer surface (sample CMS-NH2core-SHshell). For the
synthesis, a mixture of tetraethylorthosilicate (TEOS), 3-aminopropyl triethoxysilane (APTES),
phenyltriethoxysilane (PhTES), cetyltrimethylammonium chloride (CTAC) and triethanolamine
(TEA) was stirred for hydrolysis of the silanes. PhTES was used as an additive to improve the struc-
tured co-condensation with APTES in the synthesis. 30 minutes after seed generation, a thin shell of
silica was generated on the surface by adding four equal portions of TEOS to the synthesis (each with
2.5% of the total Si content of the synthesis). The outer shell of thiols was grown after an additional
aging time of 30 minutes. To this end, a mixture of TEOS and 3-mercaptopropyltriethoxysilane
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Figure 9.2: CMS samples for PpIX based drug delivery (a) CMS-CysATTO633core-PpIXshell
disulfide-bridged cysteinATTO633 in the particle’s core and covalently surface linked PpIX (represented
by red stars). (b) CMS-ATTO633core-PpIXshell with non-cleavable ATTO633 in the particle’s core and
surface linked PpIX (red stars) (c) CMS-NH2core-PpIXshell-DOPC is equipped with a DOPC lipid bilayer.
(MPTES) was added (each silane amount was 1% of the total Si content of the synthesis). The
resulting particles have sizes of around 80 nm and a pore diameter of around 4 nm. The outer sur-
face of the particles was further functionalized with a short bifunctional PEG(8) linker. In order
to provide an amino-terminated porphyrin derivative for subsequent attachment to the particle’s
PEGylated surface, protoporphyrin-IX-bis(phenyleneaminoamide) (PpIX-NH2) was synthesized (see
Figure 9.1a), following a modified procedure from the literature [261]. The obtained PpIX-NH2 can
then be attached to the particle via amidation, leading to CMS-NH2core-PpIXshell nanoparticles
(see Figure 9.1b). Synthesis success was monitored by dynamic light scattering, nitrogen sorption
measurements, ESI mass spectroscopy as well as IR and fluorescence spectroscopy.
Different particle designs can be achieved (see Figure 9.2). For disulfide-based drug delivery, the
aforementioned synthesis has been slightly modified. After CMS PEGylation, the inner amino-
functional groups were reacted with mercaptopropionic acid to obtain thiol-functional groups. The
core was activated with 2-2’-dithiopyridine (DTP), followed by reaction with ATTO633-labeled
cystein. This resulted in disulfide-bridged, ATTO633-labeled cysteine attached to the inner pore
walls of the particle core. In the last step, PpIX was covalently surface linked to obtain CMS-
CysATTO633core-PpIXshell (see Figure 9.2a). In addition, a control sample without cleavable
disulfide-linker CMS-ATTO633core-PpIXshell (see Figure 9.2b) has been synthesized.
In addition to the samples for disulfide-based drug delivery, CMS nanoparticles have been synthe-
sized for adsorptive cargo loading and release. To achieve this, CMS-NH2core-PpIXshell nanoparticles
were loaded with drugs and sealed by a SLB to prevent premature cargo release. The sample CMS-
NH2core-PpIXshell-DOPC was prepared for this purpose (see Figure 9.2c).
9.2 PpIX-induced disulfide-based drug delivery from CMS
To demonstrate the effectivity of the CMS nanoparticles with covalently surface-linked PpIX for
PCI, disulfide-based drug delivery from CMS is a well-suited strategy. The strategy is based on the
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Figure 9.3: Photoinduced endosomal release of CMS-CysATTO633core-PpIXshell and fluid
phase marker AFD inside living HuH7 cells monitored by wide-field fluorescence microscopy.
(a and b) Fluorescence microscopy images of the fluid phase marker AFD (green) and ATTO633 (magenta)
signal directly after activation of the photosensitizer. (c and d) Intensity plot of four exemplarily tracked
endosomes (highlighted by white boxes in a and b) over time. As expected, the fluorescence intensity of
AFD (c) showed a sudden decrease due to endosomal rupture. The fluorescence of core-bound CysATTO633
drops concomitantly (d). The cell nucleus is indicated by a white circle and the outer white line represents
the cell border. Scale bar: 10 µm.
reductive cleavage of disulfide bridges in the reductive milieu of the cytoplasm. In our previously
described study (see Chapter 8), we used CMS for disulfide-based drug delivery in combination
with the fluid-phase photosensitizer TPPS2a for endosomal escape. In the following experiment,
we used CMS-CysATTO633core-PpIXshell with covalently surface bound PpIX. For the experiment,
living HuH7 cells were incubated with the nanoparticles and the fluid phase marker Alexa Fluor
488 Dextran (AFD), a marker for endocytosis [45] for 12-24 hours. The incubation time of 12-
24 hours was chosen to ensure sufficient uptake of the particles into the cells and minimize effects of
cell surface-associated nanoparticles. After incubation, the cells were exposed to 405 nm laser light
with a power of 0.15 mW for up to 15 s on a wide-field microscope. Subsequently, movies of the
photoactivated cells were taken in alternating illumination with 488 and 633 nm laser light and a
frame rate of 1.7 s−1 exciting AFD and disulfide-bound CysATTO633, respectively. The fluorescence
images were recorded on two separate cameras. The first fluorescence images of the representative
movies recorded by the two cameras are shown in Figure 9.3. The images of AFD-stained endosomes
(Figure 9.3a, depicted in green) and core disulfide-bound CysATTO633 (Figure 9.3b, depicted in
magenta) co-localize to a high extend confirming intracellular localization of the particles. To
determine the kinetics of endosomal release, particle-containing endosomes were tracked in every
frame of the movie sequence in both colors. A rolling ball background filter of 5 pixels was used
to remove inhomogeneous background fluorescence in both channels. The fluorescence intensities
were extracted, normalized and plotted versus time. The AFD and CysATTO633 intensity plots
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Figure 9.4: Photoinduced endosomal release of CMS-ATTO633core-PpIXshell and fluid phase
marker AFD inside living HuH7 cells monitored by wide-field fluorescence microscopy. (a and
b) Fluorescence microscopy images of the fluid phase marker AFD (green) and ATTO633 (magenta) signal
directly after photosensitizer activation. (c and d) Intensity plot of four exemplarily tracked endosomes
(highlighted by white boxes in a and b) over time. The fluorescence intensity of AFD (c) showed a sudden
decrease due to endosomal rupture while the fluorescence of covalently core-bound dye ATTO633 remains
constant (d). The cell nucleus is indicated by a white circle and the outer white line represents the cell
border. Scale bar: 10 µm.
of four exemplary tracked endosomes are shown in Figure 9.3c and d. In case of endosomal AFD
fluorescence, destruction of the endosomal membrane is indicated by a sudden drop in fluorescence
(see Figure 9.3c, green curves) within 3 min post photoactivation. A similar effect is observed for the
CysATTO633 fluorescence of the nanoparticles in the endosomes. Concomitantly to the sudden drop
in AFD fluorescence, the same endosome shows a drop in CysATTO633 fluorescence (see Figure 9.3).
This result shows, that CysATTO633 is probably released from the endosome. Furthermore, the
drop in fluorescence intensity shows that in this experiment there is no self-quenching of ATTO633
and therefore a smaller amount of ATTO633 in bound to the CMS pores. However, photochemical
effects of the produced reactive oxygen species on the fluorescence of CysATTO633 have to be
excluded.
To evaluate this, CMS nanoparticles with non-cleavable pore-bound ATTO633 (CMS-ATTO633core-
PpIXshell) have been incubated with the cells together with AFD. After incubation, the cells were
activated by 405 nm illumination for 15 s. The movie was taken in alternating illumination with a
frame rate of 4.6 s−1. The first images of the movie sequence together with the fluorescence intensity
plots over time for both AFD and ATTO633 are shown in Figure 9.4. Endosomes for evaluation in
the intensity plots have been marked by boxes in Figure 9.4a and b. Endosomal rupture is shown
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by stepwise decrease in AFD fluorescence (Figure 9.4c, green curves). However, the fluorescence
intensity of pore-bound ATTO633 remains constant (Figure 9.4d, magenta curves). This indicates
that photochemically generated reactive oxygen species seem to have no effect on the fluorescence of
ATTO633 bound to the CMS core. Hence, the drop in fluorescence of the cleavable and pore-bound
CysATTO633 can be fully attributed to its release into the cytoplasm.
To summarize, we showed that CMS nanoparticles with covalently surface-linked PpIX are effective
in photochemical endosomal escape. However, we want to study the release mechanism in more
detail and extend PpIX-induced drug delivery to model drugs that can not be delivered in a disulfide-
based manner. Therefore, we loaded the nanoparticles by adsorption of model drugs and sealed the
nanoparticles by a SLB to prevent premature drug release.
9.3 PpIX-induced release mechanism of chromobodies from CMS
To show the functionality of the nanodevice for photoinduced endosomal release mechanistically, we
loaded CMS-NH2core-PpIXshell nanoparticles with chromobodies as model drugs and investigated
them with wide-field fluorescence microscopy in living cells. Chromobodies are epitope-recognizing
fragments of heavy-chain antibodies of Camelidae sp. fused to fluorescent proteins or dyes [262–
264]. ATTO594-labeled chromobodies were provided by Dr. Ulrich Rothbauer and Dr. Kourosh
Zolghadr from the group of Prof. Heinrich Leonhardt (LMU). The loaded and SLB-sealed parti-
cles were incubated with living HuH7 cells together with the fluid phase marker AFD. Both CMS
with supported lipid bilayer [12] and AFD [45] are known to be internalized into the cell by en-
docytosis. After 12-24 hours of incubation, the cells were exposed to 405 nm laser light for 1 min.
After photoactivation of the sample, a movie of the cell was taken in alternating illumination with
488 and 633 nm laser light and a frame rate of 3.4 s−1 exciting AFD and chromobodies labeled
with ATTO594, respectively. The first image of a representative movie sequence is displayed in
Figure 9.5. Co-localization of AFD-stained endosomes (Figure 9.5a) and chromobody-loaded CMS-
NH2core-PpIXshellDOPC nanoparticles (Figure 9.5b) confirmed successful intracellular localization
of the particles. To obtain kinetic information on the burst of the endosomes and the release mecha-
nism on the level of a single endosome, the fluorescence intensities of endosomes (marked with white
boxes and a circle in Figures 9.5a and b) were recorded and plotted versus time. Upon destruction
of the endosomal membrane, a spontaneous release and dilution of AFD into the cytoplasm was in-
dicated by a sudden drop in endosomal AFD fluorescence (Figure 9.5c, green curves). Depending on
the amount of internalized photosensitizer (PpIX), the endosomes ruptured at different timepoints
within 1 min after photoactivation. No change in fluorescence intensity was recorded for the endo-
some that did not contain chromobody-loaded CMS-NH2core-PpIXshellDOPC nanoparticles (Figure
9.5a, white circle and 9.5c, black curve). Concomitantly to the sudden drop in endosomal AFD fluo-
rescence caused by endosomal rupture, the chromobody fluorescence in the indicated regions dropped
as well (Figure 9.5d, magenta curves). Summarizing, in the first step of the cascaded delivery mech-
anism directly after photoactivation, the supported lipid bilayer is disintegrated by singlet oxygen.
This leads to the escape of chromobodies from CMS nanoparticles. However, they cannot escape
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Figure 9.5: Photoinduced endosomal release of chromobody-loaded CMS-
NH2core-PpIXshell-DOPC and fluid phase marker AFD. The cells were exposed overnight to
CMS-NH2core-PpIXshell-DOPC loaded with ATTO549-labeled chromobodies. (a,b) Fluorescence wide-field
microscopy images of the chromobody (magenta) and fluid phase marker AFD signal (green) directly after
activation of the photosensitizer. (c,d) Intensity plot of four exemplarily tracked endosomes (highlighted
by white boxes and a white small circle in a and b) over time. A rolling ball background filter of 5 pixels
was used to remove inhomogeneous background fluorescence due to released AFD and chromobodies in
both channels [217]. In case of particle-filled endosomes (white boxes in a), the fluorescence intensity of
AFD (green curves in c) showed a sudden decrease concomitant to the decrease in chromobody fluorescence
intensity (magenta curves in d) in the same region of interest due to endosomal membrane rupture and
distribution of AFD and chromobodies into the cytosol. No decrease in AFD fluorescence (black curve in
c) was detected for the endosome filled only with fluid phase marker (white circle in a). The cell nucleus is
indicated by a big white circle and the outer white line represents the cell border. Scale bar: 10 µm.
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from the endosome and no change of the endosomes’ chromobody fluorescence can be recorded. In
a second step, the endosomal membrane ruptures, indicated by fluid phase marker and concomitant
chromobody release. In addition, we observed that as a result of the 405 nm illumination of the cell,
intracellular motion of particle-filled endosomes (highlighted in white boxes in Figure 3a,b) slowed
down, as previously described [13, 30]. Strikingly, endosomes without photosensitizer (e.g. the en-
dosome highlighted with a white circle in Figure 9.5a,b) did not show such an effect. This indicates
that only endosomes containing the particle-bound photosensitizer are affected by the toxicity of
singlet oxygen on the microtubule motor proteins. In contrast to standard fluid-phase photosen-
sitizers such as AlPcS2a [265] and TPPS2a [266], the phototoxic effect can be locally restricted to
endosomes that are loaded with nanoparticles and therefore contain the covalently-bound photosen-
sitizer. This important finding shows that the covalently-bound photosensitizer enables “surgical”
endosomal release without the global cell toxicity exerted by the common photosensitizers.
9.4 Cellular effects of PpIX-induced drug release
To generalize the above approach and to verify the release and biological effects of loaded substances
on the cells, we charged two other membrane-impermeable model drugs into the pores of the CMS-
NH2core-PpIXshell. The first model drug was propidium iodide (PI), a well-known DNA and RNA
intercalator with a molecular weight of 660 Da. In addition, Alexa Fluor 647-labeled phalloidin was
applied. Phalloidin is a bicyclic peptide with a molecular weight of 1950 Da that binds to filamentous
actin. The cellular protein actin forms filaments that - among other functions - contributes to the
mechanical support of the cells [267]. As a third model drug, we used chromobodies with a molecular
weight of 13.738 Da. The chromobodies were labeled with Chromeo642 and were designed to bind
to GFP. In all cases, the particles were loaded with the corresponding model drug, sealed with a
lipid bilayer and incubated with the cells for 12-24 hours. Afterwards, the cells were exposed to
mild photoactivation conditions on a 405 nm LED plate for 5-20 min and imaged on a spinning disk
confocal microscope. As a control, we used cells that were incubated under the same conditions,
but were not photoactivated prior to imaging. The results obtained with the three model drugs
are shown in Figure 9.6. Superposition of a transmitted light image with the PI fluorescence image
(Figure 9.6a, left panel) as well as the PI fluorescence channel alone (Figure 9.6a, right panel) are
displayed. Release of PI can be visualized by diffuse magenta fluorescence in the nuclei (marked with
white circles in Figure 9.6a). Especially the nucleoli, highly contrasted structures in transmitted
light images, were stained by released PI. This can be attributed to the fact that the nucleoli, as
functional entities for the synthesis of ribosomal RNA, offer multiple intercalation sites for PI [268].
In case of phalloidin, an overlay of the peptide’s fluorescent signal (shown in magenta) with stably
actin-GFP expressing HuH7 cells (shown in green) reveals co-localization of both colors (see boxes
in Figure 9.6b). This indicates successful release and binding of phalloidin to actin fibers. As a
third proof of principle, we observed successful chromobody release and GFP binding to the tubulin
filaments of stably expressing tubulin-GFP HuH7 cells (examples of fibers are marked with boxes in
Figure 9.6c). In all three cases, non-activated control cells show only fluorescence from endosomally
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Figure 9.6: Confocal microscopy of living HuH7 cells exposed to CMS-
NH2core-PpIXshell-DOPC nanoparticles loaded with model drugs. HuH7 cells were exposed
to CMS-NH2core-PpIXshell-DOPC nanoparticles loaded with PI (a,d), phalloidin (b,e) and chromobodies
(c,f). (a) Superposition of the transmitted light image of HuH7 cells with the PI fluorescence (left panel)
and the PI fluorescence alone (right panel). Propidium iodide stains the nucleus of the cell. (b) Alexa Fluor
647-labeled phalloidin fluorescence (shown in magenta) and stably actin-GFP expressing HuH7 cell (shown
in green on the left panel) and the phalloidin fluorescence alone (shown in magenta in the right panel). (c)
Chromeo642-labeled chromobodies (magenta) released from the particles stain the microtubules of stably
microtubule-GFP expressing HuH7 cells (green, in the left panel). The chromobody channel is displayed
in the right panel. (d-f) In case of the non-photoactivated samples, no labeled cell structure was observed.
Scale bar: 10 µm.
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entrapped nanoparticles (Figure 9.6d-f). We have thus shown that the model drugs were released
from the nanoparticles in their intact form upon photoactivation, and that they were able to bind
to their respective cellular target structures.
9.5 Summary
In this chapter, we presented the use of CMS nanoparticles with covalently surface-linked PpIX as
novel photoinduced drug delivery platform. The nanoparticles were successfully applied for PCI in
living cells. In a first set of experiments, we showed disulfide-based CysATTO633 delivery from CMS.
In order to gain more mechanistic insight into the drug delivery with PS-equipped nanoparticles,
chromobodies were adsorbed into the pores and a SLB was used as a seal. The chromobodies were
released in a two-step cascaded manner. In the first step, the supported lipid bilayer is disintegrated
by singlet oxygen and in a second step, the endosomal membrane ruptures, the chromobodies can
escape and bind to their target structure. In addition, other model drugs, such as propidium iodide
and phalloidin were released from the nanoparticles in their intact form and were able to bind to
their respective cellular target structures.
To summarize, we have presented a novel photoinduced drug delivery platform consisting of mul-
tifunctional core-shell colloidal mesoporous silica nanoparticles with surface-bound photosensitizer
PpIX. This nanodevice for drug delivery is capable of stimuli-responsive and controlled, localized
endosomal escape and drug release in a two-step cascaded manner, without the global cell toxicity
exerted by common photosensitizers. We expect this method to be a powerful and general approach
for endosomal release, as the encapsulated drugs remain functional after photoactivation and release
from the nanoparticle. In addition, our delivery platform may prove very powerful for the delivery
of other membrane impermeable substances.
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List of abbreviations
abbreviation explanation
AF488 alexa fluor 488
AFD alexa fluor dextran
α-CD α-cyclodextrin
AOTF acousto-optical tunable filter
APTES (3-aminopropyl)-triethoxysilane
ASGP-R asialoglycoprotein receptor
ATP adenosine triphosphate
BfR german federal institute for risk assessment
Γ radiative decay rate
cAMP cyclic adenosine monophosphate
CB[6] cucurbit[6]uril
CdS cadmium sulfide
CHO chinese hamster ovary cells
CMS colloidal mesoporous silica
COS-7 african green monkey kidney cells
CTAB cetyltrimethylammonium bromide
CTAC cetyltrimethylammonium chloride
Cys cystein
DDAB didodecyldimethylammonium bromide
DMEM dulbecco’s modified eagle’s medium
DNA desoxyribonucleic acid
DOPC dioleoyl-sn-glycero-3-phosphocholine
DOPE dioleoyl-phosphatidylethanolamine
DOTAP dioleoyl-trimethylammonium propane
DTP 2-2’-dithiopyridine
DTT dithiothreitol
EGF(R) epidermal growth factor (receptor)
EPR enhanced permeability and retention effect
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List of abbreviations
abbreviation explanation
ESF european science foundation
FCS fetal calve serum
FDA food and drug administration
FITC fluorescein isothiocyanate
GFP green fluorescent protein
GSH glutathion
HeLa cervix adenocarcinoma cell line
HepaG2 human liver hepatocellular carcinoma cell line
HFF human foreskin fibroblast
HRBC human red blood cells
HSA human serum protein
HuH7 human hepato cellular carcinoma cell line
IUPAC International Union of Pure and Applied Chemistry
knr non-radiative decay rates
LA lactobionic acid
MDA-MB-468 human breast cancer cells
MDDC human monocyte-derived dendritic cells
ME 2-mercaptoethanol
MS mesoporous silica
MPTES (3-mercaptopropyl)-triethoxysilane
MSN mesoporous silica nanoparticles
MW molecular weight
NIH national institutes of health
PANC-1 human pancreatic carcinoma cell line
PCI photochemical internalization
PEG polyethylene glycol
PEI polyethyleneimine
PhTES phenyltriethoxysilane
PI propidium iodide
PL(G)A polylactic (co-glycolic) acid
PMV polymethacrylic acid-co-vinyl triethoxysilane
POPC 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine
78
abbreviation explanation
PpIX protoporphyrin IX
PS photosensitizer
Q quantum yield
RES reticuloendothelial system
RGD arginine-glycine-aspartic acid
(si)RNA (small interfering) ribonucleic acid
ROI region of interest
ROS reactive oxygen species
RT room temperature
SBF simulated body fluid
SLB supported lipid bilayer
SNARE soluble N-ethylmaleimide-sensitive factor attachment protein receptor
τ0 lifetime of a fluorophore
TEA triethanolamine
TEOS tetraethyl orthosilicate
TFR transferrin receptor
TPPS2a disulfonated meso-tetraphenylporphine
WHO world health organization
3T3 swiss albino mouse embryo fibroblast cell line
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